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2 Summary 
Alzheimer’s disease (AD) is a neurogenerative disease that leads to memory loss and is the most common 
form of dementia. Its main pathological hallmark is the amyloid-β (Aβ) protein in its soluble and aggregated 
forms, which according to the amyloid hypothesis triggers neurodegeneration in AD. While there are strong 
correlations between β-amyloid plaque-load and cognitive decline on an individual and group level, there 
are also numerous adults with clinically silent AD pathology. These elderly adults have significant 
accumulations of β-amyloid plaques in the absence of cognitive impairment. Several neuropathological 
changes have been shown to occur in diseased brains, including aggregation of pathological tau, vascular 
damage, alterations in brain functioning and neuroinflammation. In recent years there has been evidence 
that iron dyshomeostasis in various ways might influence the effect and progression of neurodegeneration. 
In three studies in this work we have used neuroimaging markers of β-amyloid plaques, iron, vascular 
integrity and functional connectivity to explore possible effects of iron-load in populations of cognitively 
healthy and mildly impaired older adults. In particular, Quantitative Susceptibility Mapping (QSM) MRI 
was implemented both at ultra-high field strength of 7T and high field strength of 3T, allowing for in vivo 
inferences on iron-load in cortical gray matter. 
In the first study we investigated a sample of 37 subjects of which 15 had mild cognitive impairment (MCI) 
using 7T MRI. Using functional connectivity analysis, we found altered brain functioning in subjects with 
higher iron-load. In particular in the medial prefrontal cortex a significant increase in connectivity was 
observed. From this region we extracted regional β-amyloid plaque-load and iron-load to investigate local 
interactions. Within the MCI subjects, a significant correlation was observed between both neuroimaging 
markers, indicating a co-localization of both pathologies within this region. MCI carriers of the 
Apolipoprotein E ε4 (APOE4) genetic risk factor showed both higher β-amyloid plaque-load and iron-load 
compared to cognitively healthy subjects, which only had increased β-amyloid plaque-load compared to 
non-carriers. 
In the second study we investigated a sample of 44 cognitively healthy oldest-old: healthy adults of 85 years 
and older without signs of cognitive decline. This study was performed on the 3T PET-MRI to investigate 
markers of resistance to aging associated cognitive decline by comparing the oldest-old to 36 cognitively 
healthy younger-old (aged 55-80) participants. Despite having significantly higher β-amyloid plaque-load, 
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atrophy and indicators of small vessel cerebrovascular disease the oldest-old only had slightly lower 
cognitive performance compared to younger-old. However, cortical iron-load was significantly lower in the 
oldest-old and entorhinal cortex volume positively correlated with β-amyloid plaque-load. 
In the final study a large sample of 116 cognitively healthy elderly were scanned on the 3T PET-MRI for 
simultaneous measurement of iron-load and β-amyloid plaque-load. This setup is the best possible input for 
voxel-to-voxel correlation analysis using Biological Parametric Mapping (BPM) of iron-load and β-
amyloid plaque-load. We found a bilateral pattern of strong correlations throughout the brain, most notably 
in the basal ganglia and frontotemporal cortex. No relationship between global β-amyloid burden and 
cognitive performance was observable in this cognitively healthy sample. For two bilateral clusters, located 
in the frontotemporal cortex, significant relationships between local β-amyloid and cognitive performance 
could be observed. No specific links to APOE4-carrier status was observable in the correlations or in the 
relationships of the correlations to cognitive performance. 
Taken together, in this work we have shown that neuroimaging markers of iron-load and β-amyloid plaque-
load correlate in cognitively healthy and impaired older adults. Additionally, we showed effects of iron-
load on brain functioning and relationships between APOE4 and iron-load. By investigating both MCI 
subjects and, in a separate study, healthy oldest-old subjects, we showed effects of altered iron-loading on 
cognitive performance. These findings support hypotheses of iron dyshomeostasis contributing to AD 
pathology. However, as neuroimaging studies are limited to their acquisition resolution, further studies are 
required to determine the exact location of the iron within the diseased system and to investigate 
longitudinally changes.  
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3 Zusammenfassung 
Die Alzheimerkrankheit ist eine neurodegenerative Erkrankung, die Gedächtnisverlust bewirkt und und zur 
häufigsten Form von Demenz führt. Ihr pathologisches Hauptmerkmal ist das Protein β-Amyloid in seiner 
löslichen und aggregierten Form: die Amyloid-Hypothese. Obwohl innerhalb von Personen und auf 
Gruppenebene das Ausmass an β-Amyloid-Plaques stark mit kognitivem Abbau korreliert, gibt es 
zahlreiche Erwachsene mit klinisch nicht feststellbarer Alzheimerpathologie. Diese älteren Erwachsenen 
haben signifikante Ansammlungen von β-Amyloid-Plaques aber legen keinen kognitiven Abbau an den 
Tag, oder erst in sehr viel späteren Stadien. Das Stattfinden einiger neuropathologischer Veränderungen 
wurde in Gehirnen von Erkrankten gezeigt, darunter Aggregation von pathologischem Tau, vaskuläre 
Schädigung und Neuroinflammation. In den letzten Jahren bestand Evidenz, dass Eisen-Dyshomeostase 
den Effekt und das Fortschreiten von Neurodegeneration auf vielfältige Weise beeinflussen könnte. In drei 
Studien in der vorliegenden Arbeit haben wir Neuroimaging-Marker für β-Amyloid-Plaques, Eisen, 
vaskuläre Integrität und funktionelle Konnektivität verwendet, um mögliche Effekte der Eisenbelastung in 
Populationen kognitiv gesunder und leicht beeinträchtigter älterer Erwachsener zu explorieren. 
Insbesondere wurde quantitative Suszeptibilitätskartierung (Quantitative Susceptibility Mapping; QSM) 
sowohl für Ultra-Hochfeld-MRT bei 7T als auch für Hochfeld-MRT bei 3T implementiert, was in-vivo-
Inferenzen zu kortikaler grauer Substanz erlaubte. 
In der ersten Studie untersuchten wir eine Stichprobe von 37 Personen, wovon 15 eine leichte kognitive 
Beeinträchtigung (LKB) aufwiesen, mit 7T-MRT. Mithilfe von funktioneller Konnektivitätsanalyse fanden 
wir veränderte Gehirnfunktion in Personen mit höherer Eisenbelastung. Insbesondere im medialen 
Präfrontalkortex wurde signifikant erhöhte Konnektivität beobachtet. Von dieser Region extrahierten wir 
Belastungswerte für β-Amyloid-Plaques und Eisen, um lokale Interaktionen zu untersuchen. Innerhalb der 
Personen mit LKB wurde eine signifikante Korrelation zwischen diesen beiden Neuroimaging-Markern 
beobachtet, was auf eine Kolokalisation beider pathologischer Bürden innerhalb dieser Region hinweist. 
Träger des genetischen Risikofaktors Apolipoprotein E ε4 (APOE4) mit LKB zeigten höhere 
Belastungswerte für β-Amyloid-Plaques und Eisen verglichen mit kognitiv gesunden Trägern, welche nur 
erhöhte Werte für für β-Amyloid-Plaques hatten verglichen mit Nicht-Trägern. 
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In der zweiten Studie untersuchten wir eine Stichprobe von 44 kognitiv gesunden ältesten Alten: Personen 
im Alter von 85 und mehr Jahren ohne Anzeichen kognitiven Abbaus. Diese Studie wurde mit dem 3T-
PET-MRT-Gerät durchgeführt, um Marker für Resistenz gegenüber altersbedingtem kognitivem Abbau zu 
untersuchen, wofür die ältesten Alten mit 36 kognitiv gesunden jüngeren Alten (im Alter von 55-80) 
verglichen wurden.  Die kortikale Eisenbelastung war jedoch signifikant niedriger in den ältesten Alten und 
das Volumen des entorhinalen Kortex korrelierte positiv mit β-Amyloid-Plaque-Belastung. 
In der letzten Studie wurde eine grosse Stichprobe (N=116) kognitiv gesunder Älterer mit dem 3T-PET-
MRI-Gerät gescannt zur simultanen Messung von Eisen- und mit β-Amyloid-Plaque-Belastung. Diese 
Konfiguration ist die Bestmögliche für die Voxel-zu-Voxel-Korrelationsanalyse mithilfe von biologischer 
parametrischer Kartierung (Biological Parametric Mapping; BPM) von Eisen- und β-Amyloid-Plaque-
Belastung. Wir fanden ein bilaterales Muster starker Korrelationen über das gesamte Gehirn hinweg mit 
Höchstwerten in den Basalganglien und frontotempralem Kortex. Keine Beziehung konnte zwischen 
globaler β-Amyloid-Plaque-Belastung und kognitiver Leistung gezeigt werden in dieser kognitiv gesunden 
Stichprobe. Für zwei bilaterale Cluster, lokalisiert im frontotemporalen Kortex, konnten signifikante 
Zusammenhänge zwischen lokalem β-Amyloid und kognitiver Leistung beobachtet werden. Keine 
spezifischen Verbindungen zu APOE4-Trägerstatus waren beobachtbar in den Korrelationen oder 
Beziehungen der Korrelationen zu kognitiver Leistung. 
Zusammengenommen haben wir in der vorliegenden Arbeit gezeigt, dass Neuroimaging-Marker von Eisen- 
und β-Amyloid-Plaque-Belastung in kognitiv gesunden und beeinträchtigten älteren Erwachsenen 
korrelieren. Zusätzlich haben wir Effekte von Eisenbelastung auf Hirnfunktion und Beziehungen zwischen 
APOE4 und Eisenbelastung gezeigt. Durch das Untersuchen von sowohl Personen mit LKB als auch, in 
einer separaten Studie, gesunden ältesten Alten, zeigten wir Effekte veränderter Eisenbelastung auf 
kognitive Leistung. Diese Befunde unterstützen Hypothesen eines Beitragens von Eisen-Dyshomeostase 
zur Pathologie der Alzheimerkrankheit. Da jedoch Neuroimaging-Studien durch die Auflösung ihrer 
Aufnahmen limitiert sind, werden weitere Studien gebraucht, um die exakte Lokalisierung des Eisens 
innerhalb des erkrankten Systems sowie deren potenzielle longitudinale Veränderungen zu untersuchen. 
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4 Introduction 
4.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a neurogenerative disease that leads to memory loss and is the most common 
form of dementia. In the United States, AD is the sixth leading cause of death and while since 2000 the 
number of deaths from heart disease have decreased by 14%, the number of deaths due to AD has increased 
by 69% (Association 2017). There are two main forms of AD: early-onset or familial-AD originating from 
genetic mutations, that accounts for a small number of the total number of AD cases, and sporadic-AD, 
occurring in adults over 65 years of age due to decades of pathological accumulations. Currently, one in 
nine people age 65 and older (1%) and one third (32%) of people aged 85 and older has AD (Association 
2017). While there is no medication that can stop the progression of AD related neurodegeneration at 
present, recent developments of potential drugs in clinical trials (Patel 2015; Selkoe and Hardy 2016; 
Sevigny et al. 2016) raises the hope that in the near future AD progression can be halted. 
AD is often confused with normal aging and dementia. Severe memory loss, characteristic of AD, is 
not a symptom of normal aging. It is common to have slower recall of information at higher age, 
however, cognitive decline that impacts daily life is not a normal part of the aging process. Dementia 
is defined as the significant loss of cognitive abilities severe enough to interfere with social functioning 
(McKhann et al. 2011). There are many diseases that can lead to neurodegeneration and cognitive 
decline that could be classified as dementia. As such AD can lead to dementia and it accounts for 60-
80% of dementia cases (Association 2017). Other major causes of dementia are vascular dementia, 
dementia with Lewy bodies and frontotemporal lobar degeneration. These types of dementia have 
overlapping features with AD dementia and can be identified using neuroimaging such as magnetic 
resonance imaging (MRI) and positron emission tomography (PET) or using cerebral spinal fluid 
(CSF) biomarkers. 
4.1.1 Amyloid-β (Aβ) pathology 
The main antagonist in AD has long been identified to be the amyloid-β (Aβ) protein in its soluble and 
aggregated forms, refered to as the amyloid-hypothesis (Selkoe and Hardy 2016). Aβ originates from 
proteolytic processing of the amyloid precursor protein (APP). APP itself has been implicated in a vast 
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number of neuronal processes (van der Kant and Goldstein 2015), in particular, APP seems to be involved 
in intracellular signaling pathways supporting axonal growth, dendritic process and synaptic maintenance. 
The normal regulated proteolysis of APP into its fragments regulate intracellular trafficking as well as 
neuronal migration in early embryogenesis. Additionally, APP and its fragments respond to cellular 
damaged or changes in neuronal activity by controlling cholesterol homeostasis, delivery of vesicular 
carriers, cellular growth and proliferation (van der Kant and Goldstein 2015). 
The proteolysis of APP can be amyloidogenic (resulting in generation of Aβ) or anti-amyloidogenic 
(preventing Aβ generation) depending on the specific extracellular cleavage. In the anti-amyloidogenic 
pathway, APP is cleaved by α-secretase in the APP-extracellular Aβ domain, resulting in a fragment that 
lacks the amino-terminal of the Aβ domain. However, in the amyloidogenic pathway β-secretase cleaves a 
shorter fragment, leaving the Aβ domain. In both pathways, the final step is an intra-membrane cut by γ-
secretase, resulting in Aβ (amyloidogenic) or the seemingly harmless p3 fragment (anti-amyloidogenic) 
respectively. The remaining amyloid intercellular domain (AICD) is taken up by the cytoplasm. Aβ is 
produced in this way mostly in neurons in varying lengths, where Aβ40 is the most abundant and Aβ42 the 
most aggregation prone (Masters and Selkoe 2012). 
The formation of insoluble β-amyloid plaques from Aβ monomers occurs through the formation of 
misfolded globules, followed by oligomers, β-sheet intermediates and protofibrils (Lee et al. 2011) (Figure 
1 and Figure 3). In the initial development of plaques the different stages are in equilibrium and can 
transition among each other (Serrano-Pozo et al. 2011). This initial development is followed by a secondary 
stage in which the polymerization of Aβ into fibrils and β-amyloid plaques is accelerated. This process is 
visualized in the chapter Iron in Alzheimer’s Disease. 
While not in the focus of this work, the other main pathological marker of AD is presence of neurofibrillary 
tangles (NFT) within neurons (Mandelkow and Mandelkow 2012). NFTs are the resultant of tau protein 
aggregation, which in its normal function is mainly responsible for stability and reorganization of 
microtubules within the cell. Tau protein aggregation follows a distinct pattern that is different from the 
spread of β-amyloid plaques. In general, tau pathology follows after the formation of β-amyloid plaques. 
While NFT can be viewed as a downstream effect of Aβ pathology due to phosphorylation of Tau, it has 
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also been suggested as being a necessary step for Aβ-induced-toxicity (Morris et al. 2011). Pathological 
example slices with staining for both plaques and NFT are shown below (Figure 1). 
 
Figure 1: Adapted from (Serrano-Pozo et al. 2011). Core pathological lesions observed in AD. (A) 
Plaque evident on routine H&E stained section of frontal cortex; (B) tangle in a hippocampal pyramidal 
neuron; (C) silver stain highlights both a plaque and a tangle; (D) immunohistochemistry against Ab 
highlights plaques; (E) immunohistochemistry against tau highlights tangles. 
The presence of Aβ oligomers and β-amyloid plaque build-up leads to several downstream pathologies such 
as neuroinflammation, dystrophic neurites, axonal loss and eventually neuronal loss (Benilova, Karran, and 
De Strooper 2012; Mucke and Selkoe 2012; Serrano-Pozo et al. 2011; Sperling et al. 2011; Serrano-Pozo 
et al. 2016; Jagust et al. 2009; Dubois et al. 2016). This process happens over decades in the case of late-
onset AD, making age one of the biggest risk factors for AD. At this point it is not yet clear if the β-amyloid 
plaques or the Aβ oligomers are largest source of neuronal damage and downstream pathologies. In vivo 
measures of β-amyloid plaques do relate strongly to risk for AD (Jansen et al. 2015; Pietrzak et al. 2015) 
and removal of the plaques was shown to nearly halt progressive cognitive decline (Sevigny et al. 2016). 
However, it is also suggested that AD neurodegeneration is due to Aβ oligomers released from the β-
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amyloid plaques and not due the plaques themselves (Benilova, Karran, and De Strooper 2012; Mucke and 
Selkoe 2012; Selkoe and Hardy 2016). 
While every part in the Aβ related cascades and seemingly every part of the protein has been investigated, 
it is astonishing to realize that adults with AD only have approximately 4.8 mg more Aβ protein in their 
cortical gray matter compared to controls (Roberts et al. 2017).  
4.1.2 Cerebral amyloid angiopathy (CAA) 
Capillaries in the brain can be as small as 7–10 μm in diameter with an average intercapillary distance of 
about 40 μm (Duvernoy, Delon, and Vannson 1983). This small vasculature is affected by Aβ deposits in 
the vessel walls, in particular in the medium and small-sized arteries and cortical arterioles and this 
phenomena is known as cerebral amyloid angiopathy (CAA) (Dierksen et al. 2010; Holland et al. 2008; 
Weller et al. 1998). CAA is present in almost all AD subjects to a varying degree, with up to 25% suffering 
from advanced CAA (Ellis et al. 1996). However, CAA can also be present in the absence of AD-pathology, 
with up to 50% of cases not meeting AD pathological criteria (Ellis et al. 1996; Esiri et al. 2015; Weller et 
al. 1998). In contrast to the Aβ42 that mainly makes up the β-amyloid plaques in AD, it is Aβ40 that builds 
up in the media and adventitia of small vessel walls. The build-up of Aβ in the vessel walls can result in 
total loss of smooth muscle, collagen and elastic tissue (Esiri et al. 2015). These alterations impair the 
normal functioning of the vasculature and can result in microbleeds or local infarctions. 
4.1.3 Apolipoprotein E4 (APOE4) 
The most consistent and strongest genetic predisposition for late-onset AD has been observed for mutations 
in the Apolipoprotein E (APOE) gene (Farrer et al. 1997; Corder et al. 1993; Schmechel et al. 1993), with 
an increase in the risk of developing AD up to 30 times higher in carriers of two e4 alleles (APOE4) alleles 
(Farrer et al. 1997; Corder et al. 1993; Schmechel et al. 1993).  
While the exact link between APOE4 and AD is not clear, APOE is a protein normally involved in 
formation of lipoproteins which are responsible for transport of cholesterol and other fatty acids in the 
bloodstream and the brain. However, in the literature various links have been made between AD and 
APOE4 or other APOE variants (e2 and e3). Furthermore, databases set up to identify other genetic risk 
factors have revealed that many of the top results are genes related to inflammation, cholesterol metabolism, 
transport/trafficking proteins and neuronal signaling (Bertram et al. 2008).  
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4.1.4 Changes in brain functioning 
Changes in functioning of the brain can be measured by resting-state functional MRI (rs-fMRI), revealing 
functional connectivity between brain regions based on inferences of their synchronized neuronal activity. 
The theory, measurement and analysis of rs-fMRI is explained in the Methods section of this work. With 
rs-fMRI, almost all the stages of AD progression starting from onset of clinical symptoms have been 
analyzed. The findings in AD and mild cognitive impairment (MCI) have been consistent across several 
studies. Using network analysis in a large sample of cognitively normal, MCI and AD subjects, loss of 
intra-network connectivity was shown in large networks including the default mode network (DMN), 
salience network, dorsal attention network, control network and sensory motor network (Brier et al. 2012). 
Additionally, the strength of between-network connectivity decreased between MCI and AD, indicating 
reduced coherence of brain activity. Much of research focus has been on the DMN, which is active at rest 
but has decreased activity during cognitive tasks. The DMN comprises the posterior cingulate cortex, 
medial prefrontal cortex, lateral temporal and parietal cortices, and hippocampus (Agosta et al. 2012). In 
the DMN, activity decreases with progression of AD and is even affected in subjects with higher β-amyloid 
plaque-load that do not (yet) experience cognitive decline (Sheline et al. 2010). The regions of the DMN 
are also the regions earliest involved in abnormal β-amyloid plaque depositions (Braak and Braak 1991), 
which is also suggestive of β-amyloid spreading along functionally connected regions (Seeley et al. 2007; 
Seeley et al. 2009). Other task-based fMRI studies have shown that the ability to downregulate the DMN 
during cognitive task is positivity correlated with memory performance (Hamalainen et al. 2007). 
Therefore, changes in DMN activity, in particular increases, are often investigated in relation to potential 
biomarkers. 
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4.2 Iron in Alzheimer’s Disease  
4.2.1 Iron: helpful and harmful 
Iron has been used by the earliest known organisms that existed on earth (Coby et al. 2011) and iron-
phosphide meteorites have been linked to the origins of life on earth (Pasek and Lauretta 2005). In the 
human body, iron is used for redox reactions and the majority (70%) is bound to hemoglobin within the red 
blood cells. In the brain, iron is the most abundant transition metal and essential for synthesis of 
neurotransmitters such as dopamine ATP (Lill and Muhlenhoff 2006; Meiser, Weindl, and Hiller 2013; 
Sun, Pham, and Waite 2016) and for myelination (Ortiz et al. 2004). Iron transport in the human body is 
facilitated by the transferrin protein, which can carry two iron ions each. The uptake of iron by the brain is 
regulated by transferrin receptor 1 and divalent metal transporter 1 which are highly expressed on arterial 
endothelial cells. Trafficking of iron into the brain is further tightly controlled by the blood-brain-barrier 
and in the mature brain the exchange is limited compared to other organs (Moos et al. 2007). While iron is 
essential for normal functioning, if left unbound, Fe2+ can take part in a Fenton-reaction and Haber-Wiess 
chemistry (Koppenol 2001) in which reactive oxygen species (ROS) are created that can result in cellular 
damage and accelerate cellular aging (Harman 1956; Winterbourn 1995; Dixon et al. 2012; Dixon and 
Stockwell 2014) (Figure 2). ROS have been shown to impair cellular growth and to be a source of apoptosis 
(ferroptosis) by reacting with essential amino acids, lipid peroxidation and instigating DNA damage (Dixon 
et al. 2012; Dixon and Stockwell 2014). During normal brain functioning, excess iron is stored inside the 
ferritin protein, which can hold up to 4500 iron atoms (Harrison and Arosio 1996). This is further described 
in the chapter Magnetic susceptibility (Figure 5). 
 
Figure 2: Adapted from (Dixon et al. 2012). Pathways of formation of select soluble (a) and lipid (b) 
ROS via Fenton chemistry. Key enzymes that contribute to ROS formation or detoxification are shown. 
Those whose function is iron dependent are colored blue, and the relevant iron species is in parentheses. 
SOD = superoxide dismutase, LOX = lipoxygenase. 
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4.2.2 Iron and Aβ 
The interest in iron in a context of AD originates from histopathological findings of increased iron deposits 
in brains of AD subjects and specifically around β-amyloid plaques (Andersen, Johnsen, and Moos 2014; 
Meadowcroft et al. 2009; Rottkamp et al. 2001). While copper and zinc also play an important role in brain 
functioning and have been linked to AD (Bush 2013; Squitti 2012), their concentrations in the human brain 
are significantly lower than those of iron (Deibel, Ehmann, and Markesbery 1996). 
Aβ in its monomeric and aggregated forms can bind iron, converting Fe3+ into Fe2+ (Khan, Dobson, and 
Exley 2006). While Fe3+ can bind to all forms of Aβ, it has difficulty dissociating from the fibrillar forms, 
resulting in aggregation of iron inside and on the border of the plaques (Everett et al. 2014; Derry and Kent 
2017; Peters, Connor, and Meadowcroft 2015) (Figure 3). Iron associated with β-amyloid plaques has been 
commonly observed and could be a potential source of the oxidative damage due to ROS observable in AD 
brains (Nunomura et al. 2001; Andersen, Johnsen, and Moos 2014; Meadowcroft et al. 2009; Rottkamp et 
al. 2001; Derry and Kent 2017). The ROS rich halo around plaque-bound iron can trigger ferroptosis (Dixon 
et al. 2012) and promote production of Aβ monomers due to increased β-secretase cleavage (Zhang et al. 
2007) in the cells surrounding the β-amyloid plaques. Additionally, Aβ-bound iron accelerates the extent 
and speed of aggregation from Aβ monomers into β-amyloid plaques (Peters, Connor, and Meadowcroft 
2015; Everett et al. 2014; Acosta-Cabronero et al. 2013; Ha, Ryu, and Park 2007). Subsequent white matter 
damage is also a frequent finding in AD. As white matter contains relatively large amounts of iron the 
degeneration of white matter occurring during development of AD can be a continuous source of iron-
loading (Agosta et al. 2011). 
 
18 
 
Figure 3: Image adapted from (Peters, Connor, and Meadowcroft 2015). The formation of β-amyloid 
plaques and the incorporation of iron. Β-amyloid plaque formation can be characterized by primary and 
secondary aggregation. During primary formation, ferric iron interacts with Aβ as it fluctuates between 
monomer, dimer, and tetramer formations. Iron–amyloid interactions increase ferrous iron, which can 
lead to the production of reactive oxygen species. Eventually, β-sheet intermediates and toxic soluble 
oligomers are formed from which the iron no longer can dissociate easily. Iron gets incorporated in the 
mature stable plaques and in the defuse halo around the plaques. 
ROS detection and removal mechanisms are present in healthy neuronal cells. In particular nuclear factor 
E2-related factor 2 (Nrf2) regulates the antioxidant response pathway that can buffer and degrade ROS. In 
an AD mouse model transcription of Nrf2 was shown to be reduced (Mladenka et al. 2006) while 
overexpression of Nrf2 lead to increased spatial memory (Caldeira, Ferreira, and Rego 2013). Part of the 
response to ROS is the antioxidant glutathione which is produced primarily in astrocytes and microglia. 
However, in human AD brains both cell types have been shown throughout the cortex to have reduced 
production of glutathione (Karelson et al. 2001). Both findings are indicative of reduced protection against 
iron-induced ROS in AD, resulting in increased neuropathological burden. 
There has also been evidence that APOE4 might play a role in iron homeostasis, as ferritin levels in the 
CSF predicted progression from MCI to AD in a large cohort and this effect was modulated significantly 
by APOE4 status (Ayton et al. 2015). The exact mechanism is not clear and, therefore, it was hypothesized 
 
19 
that APOE functions to lower neuronal iron as APOE knockout mice exhibit elevated brain iron (Bush 
2013; Bush et al. 2014). In a later study it was found that while controlling for APOE4-status, high CSF 
ferritin levels was predictive for increased brain β-amyloid plaque-loading in subjects with higher baseline 
levels of Aβ42 (Ayton, Diouf, and Bush 2017). 
However, investigating iron in a context of AD is complicated by the β-amyloid plaque-formation in 
transgenic mice models not completely mimicking the formation in human AD. Specifically, the β-amyloid 
plaques found in animal models exhibit opposite iron characteristics compared to human AD histology: no 
presence of focal iron and reduced free iron around the plaques due to iron binding to Aβ (Meadowcroft et 
al. 2009). Animal models more closely replicating the iron patterns found in humans are currently still 
under development. 
The pathological work by Hallgren and Sourander and recent MRI-based work (Hallgren and Sourander 
1958; Langkammer et al. 2012; Lim et al. 2013; Betts et al. 2016) have shown that brain iron-levels increase 
strongly in the first decades of life followed by stabilization around the age of 40. After this age variability 
in iron-levels strongly increase, which coincides with the assumed start of Aβ accumulation (Hallgren and 
Sourander 1958; Langkammer et al. 2012; Lim et al. 2013; Betts et al. 2016). Combined with findings of 
increased iron-loading in AD subjects (Nunomura et al. 2001; Andersen, Johnsen, and Moos 2014; 
Meadowcroft et al. 2009; Rottkamp et al. 2001; Derry and Kent 2017)  these are indications that iron 
dyshomeostasis plays a central role in development of AD. 
4.2.3 Iron modification therapies in AD 
In animal models, the iron chelator Deferoxamine was shown to decrease tau phosphorylation, slow down 
aggregation of β-amyloid plaques and reduce behavioral impairment (Guo, Wang, Zhong, et al. 2013; Guo, 
Wang, Zheng, et al. 2013). This approach was followed by a 24-month trial in AD subjects that showed 
behavioral improvements (Crapper McLachlan et al. 1991). However, there was no follow-up to this study 
and with current knowledge effects of chelation therapy are hypothesized to be only effective when 
administered in much earlier, asymptomatic, stages of life (Malecki and Connor 2002).  
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5 Hypotheses  
The information summarized previously has brought us to the following hypotheses that will be investigated 
in this work: 
1. Iron accumulation in human brains co-localizes with β-amyloid plaques in healthy and pre-clinical 
Alzheimer’s disease subjects independent from iron accumulations due to microbleeds. 
2. Iron accumulation co-localized with β-amyloid plaques in human brains negatively affects 
cognitive performance in healthy and pre-clinical Alzheimer’s disease subjects. 
3. Iron accumulation in human brains correlates with changes in functional connectivity between 
brain regions measured by fMRI. 
4. APOE-e4 genotype is associated with high β-amyloid plaque related iron accumulation. 
The main chapters will be presented in the order that the research was conducted, which is slightly different 
from the order of the hypotheses. 
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6 Methods  
6.1 β-amyloid PET 
One of the revolutions in the field of AD-diagnostics has been the development of PET tracers to measure 
β-amyloid in vivo. Until as recent as 10 years ago pathological hallmarks of AD could only be evaluated 
post-mortem (Mathis et al. 2012). The instigator of the current state of β-amyloid-plaque-PET was the 
development of the 11C-Pittsburgh Compound B (PiB) tracer. PiB is based on the Thioflavin-T, a small 
molecule used as a fluorescent dye for histological staining of protein aggregates such as β-amyloid plaques. 
Studies have shown that, as expected, PiB mostly binds to fibrillar β-amyloid such as those in plaques but 
also to vascular deposits due to CAA (Johnson et al. 2007). However, there is also strong non-specific white 
matter binding, requiring the need to mask out the gray matter for analysis. 
In order to overcome the limitation of 11C PET-tracers such as the short half-life and thus requirement of 
a production center close to the PET-scanner, 18F versions of PiB have been developed. The analogue 18F-
Flutemetamol is used in this work (Figure 4). It has similar characteristics as PiB with respect to β-amyloid 
plaque binding but also suffers from increased non-specific white matter binding, despite the only minute 
change in the chemical structure (Vandenberghe et al. 2010). Both PiB and 18F-Flutemetamol do not bind 
to Aβ oligomers, limiting the in vivo investigations into the source of neurotoxicity of β-amyloid plaques 
and anti-Aβ therapy. 
It should also be noted that the larger samples used in this study were acquired using a 3T GE Signa PET-
MRI with very fast digital PET detectors. This allows for the use of time-of-flight reconstruction, which 
enables filtering of false-positive scattered counts resulting in significantly higher signal-to-noise ratios 
(Conti 2011). 
 
Figure 4: Adapted from (Mathis et al. 2012), chemical modification of 11C-PiB to 18F-Flutemetamol,. 
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6.2 Quantitative Susceptibility Mapping (QSM) 
6.2.1 Magnetic susceptibility 
Magnetic susceptibility (χ) is a dimensionless property of a material that indicates whether a material is 
magnetized when it is placed in an external magnetic field, it can also be referred to as “magnetizability” 
(Schenck 1996). When a material interacts with the magnetic field an internal magnetization (polarization) 
is created that either opposes or amplifies the external field. If the magnetization opposes the external field, 
the material is diamagnetic. If the magnetization is amplified, the material is paramagnetic, 
superparamagnetic, or ferromagnetic, depending on the strength of the amplification. Examples of this in 
human tissues are fat (χ=-10, diamagnetic), organic free radicals (χ=+1, paramagnetic), ferritin, 
hemosiderin (χ=+5000, superparamagnetic) and pure iron (χ=+10000, ferromagnetic). Measuring magnetic 
susceptibility using MRI was envisioned at the early days of MRI (Young et al. 1987) but only recent 
developments in methodology and computer processing power have made it feasible to circumvent the 
problems involved in this type of reconstruction.  
An overview of biomedical magnetic materials that can be found in the human brain is given below, adapted 
from (Wang and Liu 2015) (Figure 5). The main sources of susceptibility contrast in the human brain are 
Fe3+ in various bound and unbound states and the myelin in the white matter. However, it is known from 
the Maxwell Equations for static magnetism that the strong susceptibility induced fields occur near the 
susceptibility edges perpendicular to the main magnetic field 𝐵0 (Li et al. 2012). This results in orientation 
dependent changes to the measured susceptibility signal in myelin. In addition to this, the susceptibility 
itself is anisotropic in myelin due to molecular anisotropy of lipid and the microstructure (Figure 5). 
Therefore, when investigating iron sources in the brain the regions of interest are limited to the gray matter. 
When interpreting the susceptibility data of gray matter regions it needs to be considered that the iron-load 
could vary on an inter-voxel basis and that QSM is biased by decreased myelin density (Langkammer et al. 
2012; Liu, Li, et al. 2011). However, the cortical and deep gray matter regions investigated in the context 
of AD are low in myelin content and thus the myelin contribution is usually considered negligible. 
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Figure 5: Biomedical magnetic materials. Adapted from (Wang and Liu 2015). (a) During metabolic 
consumption of oxygen, weakly diamagnetic oxyhemoglobin releases O2 and becomes strongly 
paramagnetic deoxyhemoglobin. (b) Blood degradation in hemorrhage. Following a hemorrhage, a small 
fraction of red blood cells (RBCs) may be endocytosed by microglia/macrophages. The majority of RBCs 
undergo cell lysis and hemoglobin (Hb) degradation from deoxyhemoglobin into methemoglobin (Fe3+) 
and hemosiderin (possible magnetic domain). Modeled after: (Keep, Hua, and Xi 2012). (c) Susceptibility 
sources in the human brain. Major susceptibility sources in (i) the brain include myelin and ferritin. The 
white matter tracts in the brain consist of myelinated nerve fibers. (ii) Zoomed view of the box in (i) 
showing axon (yellow) and myelin sheath (purple). Myelin consists of several layers of lipid bilayer. (iii) 
Zoomed view of the box in (ii) showing a lipid bilayer and an individual lipid. (iv) Ferritin in a cross-
section. Ferritin consists of a peptide spherical shell 2-nm thick with an 8-nm diameter cavity. Fe2+ enters 
through a four-fold symmetric channel, is stored as Fe3+ oxide mineral, and is released as Fe2+ through a 
three-fold symmetric channel. There are five unpaired 3d electrons in Fe3+, generating strong 
paramagnetism. 
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6.2.2 Measuring magnetic susceptibility using MRI  
Amplification of the local magnetic field due to a materials’ magnetic susceptibility adds phase 
accumulation to the protons within a measured voxel, causing dephasing or magnitude decay in T2*-
weighted MRI. In particular Gradient Echo (GRE) MRI is sensitive to this type of contrast, which can be 
used in susceptibility-weighted imaging (SWI). This type of imaging is non-quantitative because the signal 
at the local tissue is affected by all susceptibility sources around it (Figure 6). 
The effect of the susceptibility sources on the frequency map 𝛿𝐵 in any point in space can be described by 
the convolution of the dipole kernel with the surrounding susceptibility distribution χ (Jackson 1975): 
𝛿𝐵(𝑟) = ∫ 𝜒(𝑟′)
3𝑐𝑜𝑠2(𝜃𝑟−𝑟′) − 1
4𝜋|𝑟′ − 𝑟|3
𝑟′≠𝑟
𝑑3𝑟′ =
3𝑐𝑜𝑠2(𝜃𝑟) − 1
4𝜋𝑟3
⨂𝜒(𝑟) 
Where 𝛿 are the normalized field shifts, 𝑟 and 𝑟′ are the locations of the observed field and the susceptibility 
source, and 𝜃𝑟 is the angle between 𝐵0 and the vector 𝑟 − 𝑟
′. For every point in space the field shift is a 
convolution of the susceptibility distribution with the unit magnetic dipole kernel (3𝑐𝑜𝑠2(𝜃𝑟) − 1)/4𝜋𝑟
3.  
 
Figure 6: Example of the magnetic susceptibility convolution effect: (a) bar with constant susceptibility 
in a region with zero susceptibility. (b) Simulation of the resulting frequency map 𝛿𝐵 for the bar in (a). 
(c) Cross-section of the measured frequency map at the location indicated in (b). 
The convolution becomes a multiplication in the Fourier domain: 
𝐹(𝛿) = 𝐹(𝜒) (
1
3
−
𝑘𝑧
2
|𝒌|2
) = 𝐹(𝜒)𝐷(𝒌) 
With 𝐹 the Fourier transform and 𝐷(𝒌) =
1
3
− 𝑘𝑧
2/|𝒌|2, the Fourier transformed dipole kernel. This shows 
that resolving the underlying 𝜒 from the measured 𝛿 is an ill-posed problem, meaning that the solution is 
a b c 
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not stable in all regions. Due to the term 
1
3
− 𝑘𝑧
2/|𝒌|2 the de-convolution is not defined when the k-vector 
and the field direction is equal to 54.7° or 125.3°. On this conical surface in the Fourier domain the solution 
goes to infinity and there is high amplification of any noise for values on or near these cones. On the 
reconstructed image this results in streaking artifacts originating from areas with high susceptibility.  
This can be solved by oversampling the data: the direction of the susceptibility effect is dependent on the 
orientation of the source relative to the magnetic field B0. When the subject’s head is rotated relative to the 
magnetic field, the cone of undefined values is also rotated in the Fourier domain. Undefined regions of 
one orientation can then be restored by information from the other orientations (Liu et al. 2009). With 
respect to the head-angle 𝜃 and 𝜙 the dipole kernel can then be rewritten: 
𝐷𝑚𝑢𝑙𝑡𝑖(𝒌, 𝜃, 𝜙) = (
1
3
−
(𝑘𝑧 cos 𝜃 cos 𝜙 − 𝑘𝑦 sin 𝜃 cos 𝜙 + 𝑘𝑥 sin 𝜙)
2
|𝒌|2
)  
It is possible to fully reconstruct the susceptibility map with 3 orientations since any of the regions of the 3 
cones is described by well-defined data from one of the other orientations. This method is called Calculation 
of susceptibility through multiple orientation sampling (COSMOS). In a clinical setting this approach 
would be highly unpractical since a great number of patients would not be physically able to rotate their 
head in the scanner. Therefore, new methods were developed to be able to reconstruct the susceptibility 
with only 1 head orientation that use other information to reconstruct the QSM map. 
In the following sections the specific processing steps and methodology required will be described. 
6.2.3 QSM reconstruction: phase unwrapping 
To use the underlying phase data the phase wraps have to be removed. Phase wraps occurs because the 
phase data is wrapped around 2π resulting in a phase image as shown in the example image (Figure 7). To 
perform susceptibility calculations this phase wrapping must be removed. This is done in the Fourier 
domain with Laplacian based phase unwrapping by (Li, Wu, and Liu 2011). The method involves applying 
a Laplacian operator to the phase image that only uses the trigonometric functions of the phase. The 
Laplacian operator is not only insensitive to phase wraps, but also automatically removes part of the phase 
components originating from outside of the Field of View (FOV), since they satisfy the Laplacian equation 
∇2𝜃 = 0. This unwrapping is performed for each echo time (TE). 
 
26 
When the phase is unwrapped the frequency shift can be found by least squares fitting of the linear slope 
of the phase 𝜃 as a function of the TE in the first echoes for each image voxel. The magnetic field shift is 
related to the frequency shift in Hz as ∆𝑓 = 𝛾∆𝐵𝑧 2𝜋⁄ . The relative magnetic field shift in ppm can then be 
found by dividing the frequency shift in Hz by the scanner frequency. 
 
Figure 7: From left to right: 1) Raw phase data from the scanner is wrapped around 2π. 2) Unwrapping 
using Laplacian based phase unwrapping results in continuous phase information. 3) Resulting image 
after background-field removal. 
6.2.4 QSM reconstruction: background-field removal 
After phase unwrapping there are still clear slow varying phase effects present in the images. These are 
caused by the air-tissue interfaces and are an order of magnitude larger than the phase variations caused by 
local susceptibility differences. Multiple methods are developed to remove these effects without removing 
the variations due to the tissue susceptibility. The most commonly used method is the Sophisticated 
harmonic artifact reduction for phase data (SHARP) (Schweser et al. 2011) approach. This method uses 
inherent properties of the magnetic field changes both inside and outside of the brain (Figure 7).  
In SHARP we define the total susceptibility sources inside and outside the brain as 𝐵𝑡𝑜𝑡 = 𝐵𝑖𝑛𝑡 + 𝐵𝑒𝑥𝑡. 
Because the magnetic field changes outside the brain (𝐵𝑒𝑥𝑡) result from sources that are located outside the 
brain, it is harmonic throughout the entire brain, therefore it satisfies Laplace's equation throughout the 
brain itself: ∇2𝐵𝑒𝑥𝑡 = 0. The field changes inside the brain (𝐵𝑖𝑛𝑡) have their sources inside the brain they 
are inherently not harmonic. Using these properties the 𝐵𝑖𝑛𝑡 can be calculated from the total sum of sources 
by solving: 
∇2𝐵𝑡𝑜𝑡 = ∇
2𝐵𝑖𝑛𝑡 
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This equation can be solved by using the mean value property of harmonic function which stats that an 
underlying harmonic function is preserved when convolved with any nonnegative radially symmetric 
function that has a total volume of 1 (𝜌). This can be rewritten with ?̃? the underlying harmonic function of 
a magnetic field change as: 
?̃?𝑡𝑜𝑡 = 𝐵𝑡𝑜𝑡 − 𝜌⨂𝐵𝑡𝑜𝑡 = 𝐵𝑖𝑛𝑡 − 𝜌⨂𝐵𝑖𝑛𝑡 
𝐵𝑖𝑛𝑡 = (𝛿 − 𝜌)⨂
−1?̃?𝑡𝑜𝑡 
With 𝛿 the unit impulse at the center of the radial convolution kernel 𝜌. Due to size of the convolution 
kernel determines the extend to which pixels at the edge of the brain can be recovered. Smaller kernels 
result in fewer pixels lost at the edges of the brain but enforce less of the required spatial harmonicity. To 
overcome this problem smaller kernels are used near the edge of the brain while larger kernels are used in 
the center. This method is referred to as Variable spherical kernel SHARP (V-SHARP). 
During processing described in the accumulated works, V-SHARP is applied using a variable spherical 
kernel size with a maximum radius of 4mm and a regularization parameter of 0.05 (Schweser et al. 2011; 
Wu, Li, Guidon, et al. 2012). A brain mask to determine the location of 𝐵𝑖𝑛𝑡 and 𝐵𝑒𝑥𝑡 was obtained by 
skull-stripping the GRE magnitude image using FSL's brain extraction tool (BET, FMRIB Oxford, UK). 
6.2.5 QSM reconstruction: dipole inversion 
To solve the ill-posed problem at the heart of QSM it is possible to introduce a priori information to identify 
a meaningful solution. Results obtained via the multi-head-angle method COSMOS show that edge regions 
in the susceptibility image coincide with edges in the GRE magnitude images and regions with more 
constant susceptibility match more constant regions in the magnitude images. The edges showing streaking 
artifacts in the susceptibility images have artifacts that radiate away from tissue boundaries. This effect can 
be utilized to find the optimal solution by minimizing the voxels of the susceptibility gradient map that are 
not on the magnitude gradient map, thereby eliminating false gradients. The method is called Morphology-
Enabled Dipole Inversion (MEDI), which is described as an L1 norm minimization, formulated by the 
following unconstrained Lagrangian problem: 
argmin𝜒‖𝑀∇𝜒‖1 + 𝜆‖𝑊(𝛿 − 𝐹
−1𝐷𝐹𝜒)‖2
2  
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where 𝑀 is the binary gradient weighting matrix, in which the elements are 0 when they correspond to non-
negligible gradients in the magnitude image. Non-negligible gradients are defined as gradients larger than 
𝜇, a constant that needs to be optimized manually. ∇ is the 3D gradient operator, 𝜆 the Lagrangian parameter 
that needs to be optimized, 𝑊 a data weighting matrix to account for non-uniform phase noise and 𝐷 the 
dipole kernel defined earlier. The Lagrangian parameter 𝜆 determines the relative weighting of the edge 
information in the minimization. 
Simply put: this minimization will start with an almost empty “guess” of the underlying susceptibility ?̌? 
and calculate which magnetic field fluctuations (?̌?𝑖𝑛𝑡) would result from that distribution if an object was 
scanned like that. Then it compares this guessed  ?̌?𝑖𝑛𝑡 to the actually measured 𝐵𝑖𝑛𝑡 and uses the resulting 
error term to improve the estimation of the underlying susceptibility ?̌?. To improve conversion and the 
estimation we include information from the structural image (𝑀 and 𝑊) such as limiting the result to just 
brain tissue and restricting sudden jumps in susceptibility, to “push” the solution in the right direction. 
6.2.6 Improved reconstruction techniques 
Alternative methods have also been used which vary in the way they estimate the initial guess and which 
extra information to include. In areas where the gradients in the magnitude image do not match the actual 
gradients in the underlying susceptibility distribution, the previously described method would suppress the 
signal and remove contrast. To overcome this problem, the iLSQR method used in parts of this work (Li et 
al. 2015) uses a multi-step approach. First, an initial estimation is performed using a standard least squares 
(LSQR) method (Li, Wu, and Liu 2011), after which a fast and simple threshold-based inversion is 
performed to estimate susceptibility boundaries where susceptibility artifacts could occur. This information 
is then used to create a final reconstruction described as: 
𝜒𝑖𝐿𝑆𝑄𝑅 = 𝜒𝐿𝑆𝑄𝑅 − 𝐹𝑇
−1(𝑋𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡𝑠(𝑘) ∙ 𝑀𝑖𝑙𝑙−𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑒𝑑) 
Where 𝑋𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡𝑠(𝑘) are the estimated susceptibility artifacts in k-space 𝑀𝑖𝑙𝑙−𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑒𝑑 is the mask of the 
ill-conditioned regions. 
6.2.7 Interpretation of QSM measures and their quantitative value 
Because the center of the dipole-inversion kernel 𝐷(𝒌) is also undefined, all dipole-inversion 
approximation methods have in common that they can only approximate the variations (“AC”) in the image, 
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but not the constant (“DC”) component. To overcome these potential differences in estimated constant 
component between subjects, all susceptibility values have to be referenced to 1 region that is considered 
most stable for all subjects. However, it has also been shown that the effect of this constant component is 
often negligible, which is currently still debated (Betts et al. 2016). Because in the context of potential AD 
pathology all brain regions could be affected the following approach was chosen: the means of the standard 
deviations of susceptibility in commonly accepted QSM reference regions, such as various white matter 
bundles and sections of the cerebrospinal fluid, were evaluated to select the region with the lowest mean 
standard deviations as the reference region (Deistung, Schafer, et al. 2013).  
Finally, for clarity and consistency with earlier studies, changes in susceptibility values will be referred to 
as changes in iron-load, due to the previously demonstrated correlation of susceptibility values with tissue 
iron-load in brain gray matter (Deistung, Schafer, et al. 2013; Li, Wu, and Liu 2011; Lim et al. 2013; 
Schweser et al. 2012). 
6.2.8 Alternatives to QSM: susceptibility weighted, phase, T2* and R2* imaging 
Several other methods have been used to quantify the changes originating from iron which are measurable 
by MRI, before the uptick in QSM-based research. 
• Susceptibility Weighted Imaging (SWI): SWI uses the same GRE experiment as used for QSM 
to exploit the susceptibility differences between tissues and uses the phase image to detect these 
differences. Both the magnitude and phase data is saved after which high pass filtering is applied 
to remove unwanted artifacts. The magnitude and phase data are used together to create the SWI 
dataset by multiplying a phase mask image into the original magnitude image (Haacke et al. 2009; 
Mittal et al. 2009). These images are particularly sensitive to veins and as such can be used to 
investigate the vasculature. SWI images do now use point-source localization like in QSM and as 
such iron rich areas spill signal into surrounding areas. The processing and filtering also removes 
several (lower frequency) components from the signal and cannot be used for quantification. For 
clinical settings, the excellent vessel contrast makes it a good diagnostic tool. 
• Phase imaging: Using simple high-pass filtering the raw unprocessed T2* phase data can also be 
used to infer on local iron deposits since they affect the phase as discussed earlier. However, 
without QSM-processing this measurement is highly affected by non-local effects of iron or myelin 
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rich structures. Relative quantification is possible, but due to the previously mentioned non-local 
effects this method is far from precise (van Rooden et al. 2014). 
• T2* weighted imaging: The raw unprocessed T2* weighted magnitude data can reveal any 
perturbations in the magnetic field, either from iron or other underlying tissue differences. This 
makes it a great clinical tool for example in cancer imaging or other conditions that require quick 
evaluation of differences without exact quantification (Tang et al. 2014). 
• R2* imaging: Uses the multi-echo GRE data to curve-fit the T2* decay in each voxel. Has been 
shown to correlate well to iron-load in the gray matter (Daugherty and Raz 2016; House et al. 2007; 
Betts et al. 2016; Langkammer et al. 2010). R2* is a composite measure sensitive to T2 effects but 
also magnetic field inhomogeneities and can be driven by intravoxel spin dephasing near steep field 
gradients. Additionally, it is also sensitive to sources of external field fluctuation such as air cavities 
and other non-local field disturbances. Compared to QSM, R2* cannot correctly quantify very high 
iron-concentrations for example in iron-based contrast agents. Nonetheless it has been shown to be 
one of the easier alternatives to QSM that is still semi-quantitative and relates closely to local iron 
content (Langkammer et al. 2010). As myelin effects QSM (decreases the measured susceptibility) 
and R2* (increases the measured R2* value) differently, the methods can be combined to do 
quantitative analysis of myelin density in brain structures. 
6.3 FLAIR MRI  
Fluid attenuation inversion recovery (FLAIR) is a heavily T2-weighted technique resulting in the nerve 
connections of white matter to appear gray, and the congregations of neurons of gray matter to appear white, 
while the CSF appears dark (Figure 8). This is achieved by adjusting the inversion time (TI) of the FLAIR 
inversion recovery sequence such that at magnetic equilibrium there is no net transverse magnetization of 
fluid. On FLAIR images white matter hyperintensities (WMH) can be identified which are indications of 
local dysfunction of underlying axonal tracts. This can be due to breakdown of the axonal tracts or 
extravasation of fluid from the vascular system due to leakage or microbleeds. WMH have been associated 
with various cognitive disorders such as multiple sclerosis, depression and AD (Schmidt et al. 2012; 
Schreiner et al. 2014; Sperling et al. 2012). At higher age and in AD pathology, SVCD is assumed to be the 
main cause of WHM and as such a large potential source of cortical iron deposits.  
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Manual delineation of WMH is time-consuming in larger samples such as the samples used in this work, 
therefore an automated method was implemented. Each participant’s FLAIR images were segmented into 
gray matter and major white matter regions using a previously generated atlas. The WMH in each white 
matter region were automatically identified by segmenting and grouping voxels with intensities 1.5 standard 
deviation above the average gray matter intensity of each subject (Iorio et al. 2013). Automatically 
segmented regions were then and manually validated. The SVCD-burden was inferred on by summing the 
number of regions exhibiting WMH.  
The WMH score is only a rough estimator of vascular integrity because WMH can also be caused by other 
pathologies, it’s extension to the gray matter can therefore be debated. In future studies other measures of 
vascular integrity, such as contrast-enhanced MRI or PET-measures, should be used to properly investigate 
the effect of SVCD on brain iron in a context of AD. 
 
Figure 8: Example 3T FLAIR images for 2 subjects acquired as part of the imaging samples used in this 
work. Both exhibit strong white matter hyperintensities.  
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6.4 fMRI 
6.4.1 fMRI background 
Functional magnetic resonance imaging (fMRI) has made it possible to infer on brain activity in vivo 
throughout the brain, either while performing a task or with the brain at rest (Biswal et al. 1995). fMRI 
exploits a mechanism described in the previous section: Magnetic susceptibility. The change from 
oxyhemoglobin to deoxyhemoglobin alters the measured MRI signal and is therefore described as the blood 
oxygen level-dependent (BOLD) signal. The BOLD response is governed by 3 consecutive physiological 
processes: neuronal response, signaling and vascular response.  
Using simultaneous fMRI and electrophysiology it was found that the measured BOLD signal reflects the 
input and the intracortical synaptic processing rather than the spiking output of a given brain area 
(Logothetis et al. 2001). When such activation is present, there will be an increase in demand for oxygen 
and nutrients. The local neuronal environment will signal to the blood vessels (arterioles) to increase 
cerebral blood flow (CBF) in order to satisfy this demand. At onset of activation the resulting consumption 
of oxygen causes the weakly diamagnetic oxyhemoglobin to release O2, transforming it to paramagnetic 
deoxyhemoglobin, leading to a drop in measured MRI signal. This signaling occurs both through metabolic 
signaling from the increase local energy consumption and through neurotransmitter signaling. The 
respective contributions of the two factors differs across the brain. In response to the signaling the local and 
upstream vasculature responds by adapting the tone of the vascular wall in order to increase the local 
cerebral blood flow and volume (Figure 9). 
The described cascade has been validated in healthy subjects (Logothetis 2008; Logothetis et al. 2001), 
however, all three steps leading to BOLD signal can be affected by disease pathology. This can be 
advantageous when investigating baseline changes such as in resting state analysis, but can strongly affect 
results in task-fMRI where controls are compared to diseases populations.  
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Figure 9: Adapted from (Iannetti and Wise 2007). Schematic overview of the generation of the blood 
oxygen level-dependent (BOLD) signal.  
6.4.2 fMRI resting state analysis 
At the advent of fMRI analysis, the focus was on task-related fMRI in which the brain’s activity during a 
task is compared to the baseline activity to identify task-associated brain regions. It was observed that the 
BOLD signal has slow spontaneous fluctuations at rest (< 0.1 Hz), but this was initially regarded as noise 
resulting from vascular properties instead of brain activity. Later it was observed that this activity at rest is 
synchronous across brain regions, indicating functional connectivity between regions (Biswal et al. 1995) 
(Figure 10). The significance of resting state BOLD signal correlations was given little importance until 
visual representations of one of the key resting state networks, the default mode network (DMN), were 
published and were found relevant in a neuroscience context (Greicius et al. 2003). Task-related fMRI was 
not used in this work and therefore the next sections only describe resting state fMRI (rsfMRI) processing. 
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Figure 10: Adapted from (Smith et al. 2013). Basic concept of rsfMRI: calculate correlation of temporal 
activity across voxels and as such brain regions (nodes, indicated as A, B, C). 
6.4.3 fMRI resting state processing 
Before the rsfMRI scan subjects are asked to “lie still, do not think of anything in particular and to not fall 
asleep” while the BOLD signal is measured for 8 minutes (values between 5-15 minutes are common in 
rsfMRI studies). Most common MRI sequence to measure this signal is gradient echo planar imaging (EPI) 
in which one 2D slice is acquired to cover the whole brain within 2-3s with a spatial resolution of around 
3-5mm in each dimension. Consecutively a structural scan with higher resolution is acquired in order to 
map activations to brain regions. 
Various software packages are available to process the raw 4D rsfMRI data using standardized approaches. 
In this work the CONN-toolbox (Whitfield-Gabrieli and Nieto-Castanon 2012) is used in which the 
following pre-processing steps are performed:  
1. Analyze and realign changes in orientation of the rsfMRI data over time due to head motion. 
2. Warp the high resolution structural scan to Montreal Neurological Institute (MNI) standardized-
space and use the deformation matrixes to also warp the rsfMRI data to this space. 
3. Use the structural image in MNI space to generate tissue maps in order to separate non-brain 
regions, gray matter and white matter. 
4. Smoothing of the rsfMRI data is applied to improve signal-to-noise ratio and statistical power. 
5. Filtering of rsfMRI data to remove the slowest temporal drifts. 
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6. Regression of motion parameters (estimated in step 1) and signal changes from the CSF. 
7. Independent component analysis (ICA) identifying noise components which are subsequently 
removed.  
After pre-processing temporal synchronicity between spatially separated voxels needs to be calculated 
(Figure 10). This can either be done in a seed-based approach, in which a seed region is selected and time 
courses in all other voxels are compared to the seed region, or an ICA analysis to identify similar 
components throughout the brain (Cole, Smith, and Beckmann 2010). While seed-based approach allows 
for less variation due to possible underlying changes since the seed is fixed, ICA requires manual 
identification of significant components and is less established. Both techniques are used throughout 
currently published works, with a tentative preference for ICA in more recent works.  
When the networks are identified, comparisons can be made on a group or linear-correlation basis. Either 
participants are grouped based on some classifier and the same network is compared between the two 
groups, or within the selected network voxels are weighted by a linear value for each subject and evaluated 
for significance within the whole sample. The statistics involved for these large 4D datasets is called 
Statistical Parametric Mapping (SPM) (Friston 1994), in which a General Linear Model (GLM) is used to 
describe the statistical contrast being tested as a correlation between measurements and a design matrix 
with a noise term. Correction for multiple testing is handled by applying Gaussian random fields theory 
(Friston 1994) after T-testing of each voxel for significance. 
6.5 Volumetric analysis 
Volume loss of gray matter, particular in memory regions such as the hippocampus and temporal lobe (Ball 
et al. 1985), is a common feature of AD. Reduced hippocampal volume correlates to early memory decline, 
however, it is also a feature of other dementias and even of regular aging (Driscoll et al. 2003). In this work 
we did not focus particularly on advanced volumetric analysis, such as Voxel-based morphometry (VBM) 
(Mechelli et al. 2005) or advanced hippocampus sub-segmentations (Pipitone et al. 2014).  
To analyze local iron and β-amyloid plaque-load subject-specific segmentations are required to select 
regions of interest (ROIs). While many standardized approaches are available for segmentation in software 
packages like SPM, they are based on healthy brains and are not very well suited for diseased brains which 
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can be anthropic or have enlarged ventricles. Therefore, the T1-weighted image was segmented using a 
multi-atlas matching approach consisting of 143 Regions of Interest (ROIs) developed as part of the Johns 
Hopkins University brain atlas. The atlas system is optimized for the parcellation of potential non-healthy 
brains by applying a Multiple-Atlas Likelihood Fusion algorithm and Ontology Level Control technology 
on the JHU multi-atlas sets (Djamanakova et al. 2014; Tang et al. 2013; Mori et al. 2016). Specifically, the 
atlas set of 26 participants aged between 50 and 90 years was used to cover all possible types of brain 
morphologies in the investigated populations. 
To normalize different brain sizes across participants, individual structural volume was corrected with the 
following approach: Corrected structure volume = Original structure volume × (whole sample mean 
intracranial volume / participant intracranial volume). To investigate possible relationships between 
structure volume and local β-amyloid plaque-load or local iron-load, gray-matter regions of interest (ROIs) 
were selected from the generated atlas based on earlier reports on distribution of brain pathology at early 
stages of AD (Frisoni et al. 2010; Serrano-Pozo et al. 2011). ROI-masks were eroded with two pixels to 
account for partial volume effects before being used as a mask to analyze average iron-load (QSM) and β-
amyloid burden. 
6.6 Biological Parametric Mapping (BPM) 
The Biological Parametric Mapping (BPM) toolbox (Casanova et al. 2007; Yang et al. 2011a, 2011b) is an 
extension of the previously described SPM analysis to evaluate voxel wise correlations between two 
imaging modalities while controlling for covariates. The SPM analysis only has one statistical result for 
each voxel when checking for significance using random fields theory, because there is only one T/F-test 
result per voxel (Figure 11). When correlating two modalities per subject, each voxel in the resulting 
statistical image has the correlation statistic for each subject (Figure 11). Therefore, BPM uses an adapted 
version of the random fields theory for 3D correlation volumes. 
The main limitation of this approach is that all data needs to be converted to standard space, usually MNI-
space. In case of fMRI data the lower resolution and general smoothness of the signal mitigates issues to 
sub-optimal transformation to standard space. However, in higher resolution images such as QSM or β-
amyloid-PET that also are strictly limited to being relevant in gray matter, quality of transformation could 
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be a significant issue. Therefore, the optimized conversion to standard space of the Johns Hopkins 
University was used. 
As described previously, the larger samples used in this work were acquired on an integrated PET-MRI, 
limiting distortion by processes of co-registration of PET with MRI images or bias due to changes occurring 
in the time between PET and MR acquisition. 
 
Figure 11: Adapted from (Casanova et al. 2007). Differences between SPM analysis (left) and BPM 
analysis (right). In SPM all voxels have the same design matrix with set values for each voxel (left, 
column 3), while in BPM each voxel has a unique design matrix where it contains the unique imaging 
values for each subject in that voxel (right, column 3). 
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7.1 Abstract 
Quantitative Susceptibility Mapping (QSM) MRI at 7 Tesla and 11-Carbon Pittsburgh-Compound-B PET 
were used for investigating the relationship between brain iron and amyloid beta (Aβ) plaque-load in a 
context of increased risk for Alzheimer's disease (AD), as reflected by the Apolipoprotein E ε4 (APOE-e4) 
allele and mild cognitive impairment (MCI) in elderly subjects. Carriers of APOE-e4 with normal cognition 
had higher cortical Aβ-plaque-load than non-carriers. In MCI an association between APOE-e4 and higher 
Aβ-plaque-load was observable both for cortical and subcortical brain-regions. APOE-e4 and MCI was also 
associated with higher cortical iron. Moreover, cerebral iron significantly affected functional coupling, and 
was furthermore associated with increased Aβ-plaque-load (R2-adjusted=0.80, p<0.001) and APOE-e4 
carrier status (p<0.001) in MCI. This study confirms earlier reports on an association between increased 
brain iron-burden and risk for neurocognitive dysfunction due to AD, and indicates that disease-progression 
is conferred by spatial colocalization of brain iron deposits with Aβ-plaques.   
 
40 
7.2 Introduction 
Alzheimer's disease (AD) is the most frequent cause of dementia and significantly increased risk for AD-
dementia is associated with advanced age, mild cognitive impairment (MCI) and carrier-status of the 
Apolipoprotein E ε4 allele (APOE-e4)(Corder et al. 1993). Neuropathological hallmarks of AD include 
both intracellular pathological neurofibrils as well as extracellular accumulation of amyloid beta (Aβ) 
plaques (Morris et al. 2010; Schmechel et al. 1993). Particularly the accumulation of Aβ-plaques is 
considered to potentially represent preclinical disease stages (Liu et al. 2015; Sperling et al. 2015; Nitsch 
and Hock 2008). The APOE-e4 allele has been shown to be closely associated with the extent of cerebral 
Aβ-plaque-load (Reiman et al. 2009) and both exert interactive effects on cognitive decline (Mormino, 
Betensky, Hedden, Schultz, Amariglio, et al. 2014; Mormino, Betensky, Hedden, Schultz, Ward, et al. 
2014). Recent data demonstrate that the risk for developing AD-dementia, as conferred by APOE-e4 carrier 
status, is closely linked to cerebral iron-burden, implicating potential benefit of therapeutic strategies aimed 
at lowering brain iron in this patient population (Wood 2015; Ayton et al. 2015).  
Accumulation of iron in the human brain is a characteristic finding in several neurodegenerative disorders 
(Barbosa et al. 2015; Murakami et al. 2015) and has been reported for AD both in post-mortem studies 
(House et al. 2007; Bush 2013; Connor, Menzies, et al. 1992; Connor, Snyder, et al. 1992) as well as in 
vivo by using magnetic resonance imaging (MRI) (Bartzokis et al. 2000; Bartzokis and Tishler 2000; 
Acosta-Cabronero et al. 2013). In its normal function, amyloid precursor protein (APP) facilitates iron 
transport outside the cell (Duce et al. 2010). In mammalian cell cultures iron has been demonstrated to 
interfere in the aggregation of Aβ and thus may significantly promote Aβ neurotoxicity in AD (Liu, 
Moloney, et al. 2011). Additionally, local iron deposits are considered to reflect mitochondrial dysfunction 
(Bishop, Lu, and Yankner 2010) and abnormal microglial activation (Zeineh et al. 2015) in a context of 
pathological brain change taking place in AD. Recent developments on quantitative susceptibility mapping 
(QSM) techniques (Deistung, Schafer, et al. 2013; Lim et al. 2013; Langkammer et al. 2012; Schweser et 
al. 2012; Li, Wu, and Liu 2011) have made it possible to directly map brain tissue magnetic susceptibility, 
which has been shown to correlate well with tissue iron concentration in cerebral gray matter (de Rochefort 
et al. 2010; Deistung, Schafer, et al. 2013; Lim et al. 2013; Langkammer et al. 2012; Schweser et al. 2012; 
Li, Wu, and Liu 2011).  
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Positron Emission Tomography (PET) for measuring cerebral Aβ-plaque-load has been combined with 
functional MRI (fMRI) at rest for inferring on functional network integrity, in several studies so far that 
included both cognitively normal populations of elderly subjects, as well as individuals with MCI and 
manifest AD-dementia (Huijbers et al. 2014; Sperling et al. 2009; Johnson, Sperling, and Sepulcre 2013). 
Interestingly, there is a significant overlap between brain regions characterized by altered functional 
connectivity and localization of AD-pathology (Mintun et al. 2006). This overlap particularly affects 
structures connected with the medial prefrontal cortex (MPFC), which is a central hub within the default-
mode network (DMN) and thus is considered to have spatially specific effects on neuronal functionality, as 
reflected by downstream memory deficits (Buckner 2005; Sheline et al. 2010; Sperling et al. 2010; Ward 
et al. 2014). The application of MRI at ultra-high field strength of 7 Tesla (7T) inherently increases signal 
to noise ratios (SNR) in QSM and BOLD fMRI, due to the linear relationship between susceptibility 
induced field shift and field strength, and supralinear relationship between BOLD contrast and field 
strength, respectively, allowing for  detecting subtle changes in the brain with relatively small sample size 
(Hua et al. 2011; Hua et al. 2014; Schweser et al. 2012). 
At this point several neuropathological and neuroimaging studies have demonstrated the close relationship 
between increased risk for AD and prevalence of MCI, APOE-e4 carrier status, Aβ-plaque-load and altered 
functional connectivity (Sperling et al. 2011), and also an association between APOE-e4 carrier status and 
increased brain iron-load (Ayton et al. 2015). However, to our knowledge there are no studies published on 
the impact of brain iron-load on functional brain network integrity and prevalence of regional Aβ-plaque-
load in subjects at risk for AD. As the extent of regional Aβ-plaque-load may be estimated by applying 
radioactive tracers such as 11C-Pittsburgh Compound B for PET (PiB-PET) (Klunk et al. 2004; Solbach et 
al. 2005) and cerebral iron can be measured by QSM (Langkammer et al. 2012), the combination of QSM 
with PiB-PET can be used to infer on Aβ-plaque related iron-load. Thus, for the current study the following 
questions were investigated in a study population of elderly subjects with normal cognitive performance 
and MCI:  
A) To investigate a potential relationship between increased AD-risk, as reflected by MCI and APOE-e4 
carrier-status, with cerebral iron-burden, as measured by whole-brain QSM at ultra-high field strength 
of 7T. 
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B) To estimate combined effects of MCI and increased cerebral iron-load on MPFC-coupling by resting 
state BOLD fMRI.  
C) To characterize the relationship between iron-load and Aβ-plaque density in brain regions with altered 
MPFC-coupling by whole-brain QSM and 11C-PiB-PET data. 
7.3 Methods 
7.3.1 Participants 
37 study participants aged between 62 and 89 years (22 cognitively normal, 15 MCI) without evidence of 
significant medical illness, were recruited as part of an ongoing study at our hospital. The study was 
conducted in accordance with good clinical practice guidelines issued by the local ethics committee 
(Kantonale Ethikkommission Zürich), as well as with the declaration of Helsinki. All procedures were 
approved by the Kantonale Ethikkommission Zürich. Written informed consent was obtained from all 
participants before inclusion in the study. 
All participants received psychiatric examination and neuropsychological testing during screening for 
eligibility to participate in the current study and were categorized either as cognitively normal or MCI 
according to established criteria for diagnosis of MCI (Petersen et al. 1999; McKhann et al. 2011). 
Neuropsychological tests included Mini Mental State Examination (Folstein, Folstein, and McHugh 1975) 
(MMSE), Montreal Cognitive Assessment (Nasreddine et al. 2005) (MOCA), Verbal Learning and Memory 
Test (Helmstaedter and Durwen 1990) (VLMT), Wechsler Memory Scale (Howard 1950) (WMS), Boston 
Naming Test (Nicholas et al. 1989) (BNT) and Trail Making Test (Tombaugh 2004). Clinical examination 
including clinical workup and neuropsychological testing were administered within 30 days of the PiB-PET 
scan and 7T MRI scan. Isoforms of the APOE gene were assessed for all participants (Tanzi 2012). 
Exclusion criteria for the current study were: severe cognitive deficits indicating dementia, significant 
medication or drug abuse with possible effects on cognition, 7T MRI exclusion criteria (such as history of 
claustrophobia, vertigo, seizure disorder, middle-ear disorder, double vision and the presence of metals in 
or on the body), MRI scans with the evidence of infection, infarction, or other focal lesions, clinically 
relevant changes in red blood cell count, exclusion criteria for PiB-PET, history of severe allergic reactions 
to drugs or allergens, serious medical or neuropsychiatric illness and significant exposure to radiation. 
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7.3.2 Carbon-11 based Pittsburgh compound B Positron Emission Tomography (PiB-PET) 
for estimation of brain Aβ-plaque density 
PiB-PET based estimation was used to estimate individual brain Aβ-plaque-load (Klunk et al. 2004). 
Individual dose of 350MBq of carbon-labelled PiB was injected into the cubital vein. Standard quantitative 
filtered back projection algorithm including necessary corrections was applied. Cerebral Aβ deposition 
values were extracted using PMOD Brain Tool software-package (PNEURO, Version 3.4, PMOD 
Technologies Ltd, Zürich, Switzerland). Late frame (minutes 50-70) values were standardized by the 
cerebellar gray matter average, resulting in 3D-volumes of PiB-PET retention (matrix=128x128x47, voxel 
size=2.3x2.3x3.3 mm). As a single measure of individual cortical Aβ-plaque-load, cortical PiB retention 
scores were determined by calculating a composite score using merged cortical PiB-PET intensity values, 
as reported earlier (Vandenberghe et al. 2010). 
7.3.3 MRI data acquisition 
All subjects were scanned using a Philips 7-Tesla Achieva whole-body scanner (Philips Healthcare, Best, 
The Netherlands) equipped with a Nova Medical quadrature transmit head coil and 32-channel receive coil 
array. A T1-weighted MP2RAGE image (TR/TE = 4.8ms/2.1ms, voxel size=0.6x0.6x0.6mm3, SENSE-
factor=2x1x2, scan duration=7:50min) was acquired for anatomical referencing and automated image 
segmentation. MR phase measurements used for QSM calculation were acquired using a multi-echo 3D 
gradient recalled echo (GRE) sequence with 3 echoes (TR/TE/ΔTE=23/6/6ms, flip angle=10°, voxel 
size=0.5x0.5x0.5mm3, SENSE-factor=2.5x1x2, flow-compensated, scan duration=13:48min). Phase data 
acquired with an echo time in the range of 12-18ms was used for QSM reconstruction. rs-fMRI was acquired 
using 3D T2-prep GRE sequence (Hua et al. 2014) (TR=2s, TRGRE/TEGRE=3.08/1.6ms, voxel 
size=1.5x1.5x1.5 mm3, scan duration=7:03min).  The high resolution GRE images were inspected (by P.U.) 
for any imaging artifacts or abnormalities, in particular cerebral microhaemorrhages (microbleeds).  
7.3.4 MRI data processing 
7.3.4.1 Quantitative susceptibility mapping (QSM) for measuring brain iron-load 
Multiple processing steps were performed to calculate from acquired MR phase images the quantitative 
susceptibility maps of which local cerebral iron-load is inferred. First, phase unwrapping was performed 
using Laplacian based discrete phase unwrapping (Li, Wu, and Liu 2011). A brain mask was then obtained 
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by skull-stripping the GRE magnitude image acquired at TE of 12ms using FSL's brain extraction tool 
(BET, FMRIB Oxford, UK) with fractional threshold of 0.3. The unwrapped phase images were then 
divided by 2π*TE to obtain an image of the frequency shift in Hz for each echo. Subsequently, background 
fields were eliminated with the sophisticated harmonic artifact reduction for phase data (SHARP) 
(Schweser et al. 2011) approach using a variable spherical kernel size with a maximum radius of 4mm and 
a regularization parameter of 0.05 (Schweser et al. 2011). After removal of background fields, the resulting 
images of the two echoes were averaged to obtain a higher SNR as compared to single echo reconstruction 
(Wu, Li, Avram, et al. 2012; Wu, Li, Guidon, et al. 2012). Inverse dipole calculations to obtain the 
susceptibility maps were performed using a LSQR based minimization (Li, Wu, and Liu 2011). From 
suitable reference regions such as white matter tracts and central cerebral spinal fluid (CSF) regions 
(Deistung, Schafer, et al. 2013; Deistung, Schweser, et al. 2013), the region having the lowest standard 
deviation of mean susceptibility in all subjects was selected. In this sample the frontal central CSF region 
in the lateral ventricles was selected as a reference region for the final susceptibility quantification. All 
reported susceptibility values are then relative to the mean susceptibility value of this reference region. 
Classification of all subjects as “high” or “low” cerebral iron content was performed by a median split of 
the average cortical gray matter susceptibility of all subjects, in the same regions used for the determination 
of the individual cortical Aβ-plaque-load (Vandenberghe et al. 2010). 
7.3.4.2 Assessment of structure volumes and mean susceptibility 
In order to assess atrophy and susceptibility differences between MCI subjects and controls, the T1-
weighted image was co-registered to the GRE magnitude image. The co-registered T1 image was then 
segmented using a multi-atlas matching approach developed as part of the Johns Hopkins University brain 
atlas, which is optimized for the parcellation of non-healthy brains (Tang et al. 2013; Djamanakova et al. 
2014). ROIs were selected in the basal ganglia and several cortical gray matter structures for which mean 
susceptibility was calculated after eroding the ROI-masks with two pixels (1mm) to account for partial 
volume effects and possible edge artifacts in cortical ROI’s. To normalize different brain sizes across 
subjects, individual structural volume was corrected with the following approach: Corrected structure 
volume = Original structure volume × (group mean intracranial volume / subject intracranial volume). 
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7.3.4.3 fMRI analysis  
Pre-processing of the rs-fMRI data was performed using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/), the 
following steps were performed: realignment, slice time correction, co-registration of structural scan, 
segmentation, normalization and smoothing (FWHM=4). The iron classification and MCI status were used 
as the covariates of interest in connectivity analysis using the CONN toolbox (Whitfield-Gabrieli and Nieto-
Castanon 2012). The signal was filtered with a band-pass filter using the default CONN setting of 0.01–0.1 
Hz. Seed-to-voxel analysis was performed with the seed placed in the MPFC. Motion parameters (extracted 
using the Artifact Detection Tool, ART, https://www.nitrc.org/projects/artifact_detect/), CSF, and white 
matter were regressed out, as variables of no interest. Connected voxels were included in the mask if they 
had a False Discovery Rate (FDR) corrected probability of p<0.001. Using this mask gray matter 
susceptibility and PiB-PET retention values were extracted and averaged for each subject. 
7.3.5 Statistics 
To examine the differences between groups 1-way MANCOVA was performed with the mean magnetic 
susceptibility or tissue volume of each brain structure as the outcome variable, while controlling for age 
and gender, followed by False Discovery Rate (FDR) multiple testing correction (Benjamini and Hochberg 
1995). Effect sizes were calculated using Cohen’s d. All statistical tests were performed using MATLAB 
R2014b (Mathworks, Natick, MA). 
7.4 Results 
7.4.1 Demographics of the study population. 
Demographic information for the investigated study population and neuropsychological test performance 
at time of inclusion are summarized in Table 1. MCI and healthy controls differed significantly in scores 
on the neuropsychological tests MOCA, VMLT, Boston Naming Test and WMS. Example PiB-PET images 
and QSM maps can be seen in Figure 1. Cortical PiB-PET retention differed significantly (p=0.006, effect 
size=3.1) between the two groups. The frontal central CSF region in the lateral ventricles, which was used 
as a reference for susceptibility calculations, was significantly different in volume (healthy: 19.1 ± 2.0 ml, 
MCI: 24.2 ± 3.3 ml, p < 0.05) but not in absolute susceptibility ppb reading before referencing (healthy: 
5.8 ± 1.1 ppb, MCI: 5.6 ± 1.1 ppb). For all subjects, the median split of the average cortical PiB-PET 
retention was found to be 1.13 and the median split of the average cortical susceptibility was 3.0 ppb. 
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Accordingly, the study population was classified based on PiB-PET retention into “high” and “low” cortical 
PiB (“high”: 7 healthy, 11 MCI) and susceptibility for iron -load (“high”: 10 healthy, 8 MCI). 
  Controls MCI  
N (F/M) 8 / 14 5 / 10 
Age (years) 71.91 ± 5.25 75.27 ± 7.63 
Education (years) 13.64 ± 2.56 15.2 ± 3.51 
PiB-PET retention 1.16 ± 0.08  1.5 ± 0.17 ** 
APOE-e4 positive 7 (31%) 6 (40%) 
MMSE 29.27 ± 0.70 28.61 ± 1.65 
MOCA 27.36 ± 1.30 24.44 ± 2.17 ** 
VLMT: immediate recall 11.59 ± 2.22 7.11 ± 4.00 *** 
VLMT: delayed recall 11.41 ± 2.94 6.83 ± 4.29 *** 
VLMT: recognition 12.73 ± 2.31 7.78 ± 5.79 ** 
Boston Naming Test 14.68 ± 0.48 13.94 ± 1.26 * 
WMS: pairs learning 14.76 ± 4.28 10.65 ± 4.72 ** 
WMS: pairs recall 5.52 ± 1.49 3.88 ± 1.75 ** 
Verbal Working Memory 6.32 ± 1.99 5.44 ± 1.42 
Trail Making Test ratio 2.58 ± 0.74 2.6 ± 1.24 
Table 1: Demographic data and clinical assessment scores for control subjects with normal cognition 
and MCI subjects at time of inclusion in the study. Data are presented as mean ±standard deviation. 
APOE-e4 status presented as N (percentage of group). Age and Education are in years. * Significant 
difference between controls and MCI with p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 1: Example images for a control subject (left) and MCI subject (right). The top row shows PiB-
PET images of Aβ-plaque-load in gray matter, which is highly increased in the frontal regions in the MCI 
subject, the signal in the white matter is non-specific to Aβ-plaque-load and is also observed in the 
control subject. The bottom row shows QSM maps of the same slices indicating regions with high iron-
load such as the basal ganglia.  
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7.4.2 Effects attributable to MCI and APOE-e4 carrier status. 
Corrected volume was significantly different between controls and MCI subjects in the amygdala, 
hippocampus, thalamus and putamen with p<0.001 and effect sizes of 0.80-1.2 (Table 2). However, no 
significant differences were found for the average susceptibility in any of these regions between the two 
groups.  
  
Corrected volume (ml)  
Mean ± STE 
χ (ppb)  
Mean ± STE 
  Controls MCI Controls MCI 
Amygdala 4.03 ± 0.09 3.60 ± 0.15 *** -16.6 ± 2.3 -17.4 ± 2.3 
Nucleus Acc 1.76 ± 0.07 1.84 ± 0.10 11.8 ± 3.7 11.8 ± 5.5 
Hippocampus 8.62 ± 0.18 7.55 ± 0.22 *** -1.3 ± 1.7 -0.6 ± 2.9 
Entorhinal Ctx 2.15 ± 0.13 2.01 ± 0.15 23.4 ± 3.8 25.8 ± 3.3 
Thalamus 13.88 ± 0.19 12.83 ± 0.40 *** -7.7 ± 1.8 -8.9 ± 1.8 
Caudate Nucleus 9.53 ± 0.24 9.31 ± 0.30 41.4 ± 4.2 38.2 ± 3.7 
Putamen 10.11 ± 0.27 8.92 ± 0.43 *** 63.6 ± 4.4 61.2 ± 4.3 
Globus Pallidus 3.50 ± 0.07 3.35 ± 0.09 104.5 ± 4.9 99.3 ± 5.0 
Frontal Ctx 16.56 ± 1.98 16.13 ± 2.36 2.1 ± 1.8 2.6 ± 2.2 
Temporal Ctx 23.24 ± 2.40 22.13 ± 2.77 0.3 ± 1.6 2.1 ± 2.1 
Parietal Ctx 21.63 ± 1.13 21.23 ± 1.32 4.3 ± 1.6 4.0 ± 1.8 
Occipital Ctx 18.76 ± 2.51 18.38 ± 2.93 3.6 ± 1.8 3.8 ± 2.1 
 Table 2: Changes in corrected volume and susceptibility (referenced to CSF) between controls and MCI. 
Ctx = Cortex. Data are presented as mean ± standard error (STE). *** Significant difference between 
controls and MCI with p < 0.001. 
Splitting the analysis based on MCI and APOE-e4 status showed no significant susceptibility differences 
in cortical regions of control subjects but strong significant increases in APOE-e4 carriers in the caudate 
nucleus (Table 3, p<0.01, effect size=1.03) and frontal, temporal, parietal and occipital cortices (p<0.001, 
effect sizes=0.67-1.11) for the MCI group. APOE-e4 positive subjects had significantly higher levels of 
Aβ-plaque-load in general, as indicated by PiB-PET retention (APOE-e4 positives: 1.56±0.12, APOE-e4 
negatives, 1.17±0.04, p=0.006). There was no significant effect of APOE-e4 status on the volume for any 
of the investigated cortical and subcortical regions (data not shown).  
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Iron-load 
(χ, ppb) 
Mean ± STE  
Aβ-plaque-load  
(PiB-PET, SUVR)  
Mean ± STE  
 APOE-e4 - APOE-e4 + d APOE-e4 - APOE-e4 + d 
A) Controls 
Amygdala -17.2  ± 2.5 -15.3  ± 2.2 0.19 1.19  ± 0.02 1.19  ± 0.02 0.02 
Nucleus Acc 12.1  ± 4.1 11.2  ± 3.2 0.06 1.17  ± 0.02 1.23  ± 0.03 0.64* 
Hippocampus -1.4  ± 1.7 -1.2  ± 2.1 0.02 1.25  ± 0.02 1.31  ± 0.02 0.70* 
Entorhinal Ctx 22.6 ± 5.1 25.0 ± 2.6 0.15 1.08  ± 0.02 1.14  ± 0.01 0.92** 
Thalamus -6.5  ± 1.9 -10.5  ± 1.4 0.55 1.48  ± 0.04 1.48  ± 0.04 0.01 
Caudate Nucleus 46.0  ± 3.7 31.5  ± 5.5 0.75* 1.26  ± 0.03 1.28  ± 0.03 0.23 
Putamen 67.2  ± 4.3 55.9  ± 5.3 0.56 1.33  ± 0.02 1.36  ± 0.01 0.46 
Globus Pallidus 106.4  ± 5.0 100.4  ± 5.7 0.26 1.45  ± 0.02 1.50  ± 0.04 0.34 
Frontal Ctx 2.6  ± 1.9 1.1  ± 2.0 0.18 1.02  ± 0.03 1.13  ± 0.04 0.69*** 
Temporal Ctx 0.7  ± 1.6 -0.6  ± 2.0 0.17 1.04  ± 0.02 1.10  ± 0.04 0.48*** 
Parietal Ctx 4.1  ± 1.6 2.7  ± 1.8 0.25 0.99  ± 0.02 1.15  ± 0.05 1.07*** 
Occipital Ctx 4.0  ± 1.9 2.9  ± 1.8 0.14 1.14  ± 0.03 1.19  ± 0.04 0.42** 
B) MCI 
Amygdala -17.5  ± 1.8 -17.2  ± 2.6 0.04 1.07  ± 0.02 1.54  ± 0.03 4.01*** 
Nucleus Acc 8.2  ± 4.9 17.3  ± 4.7 0.44 1.16  ± 0.02 2.41  ± 0.07 7.00*** 
Hippocampus -2.0  ± 2.0 1.5  ± 3.5 0.31 1.14  ± 0.03 1.42  ± 0.03 2.55*** 
Entorhinal Ctx 23.1 ± 3.4 30.0 ± 2.5 0.56 1.02  ± 0.03  1.31  ± 0.03 2.80*** 
Thalamus -9.1  ± 1.4 -8.5  ± 2.1 0.07 1.46  ± 0.02 1.80  ± 0.06 1.95*** 
Caudate Nucleus 32.7  ± 2.0 46.3  ± 4.5 1.03** 1.24  ± 0.04 2.13  ± 0.09 3.40*** 
Putamen 58.6  ± 3.7 65.2  ± 4.0 0.41 1.29  ± 0.01 2.23  ± 0.05 7.29*** 
Globus Pallidus 96.4  ± 3.3 103.5  ± 6.3 0.36 1.41  ± 0.03 1.92  ± 0.06 2.86*** 
Frontal Ctx 0.1  ± 1.6 6.3  ± 2.2 0.78*** 0.98  ± 0.05 1.95  ± 0.10 3.32*** 
Temporal Ctx 0.0  ± 1.8 5.2  ± 1.8 0.67*** 1.03  ± 0.02 1.73  ± 0.07 3.50*** 
Parietal Ctx 1.3  ± 1.2 8.1  ± 1.8 1.11*** 1.00  ± 0.03 1.87  ± 0.09 3.60*** 
Occipital Ctx 1.5  ± 1.4 7.2  ± 2.4 0.71*** 1.13  ± 0.02 1.59  ± 0.08 2.20*** 
Table 3: Quantitative magnetic susceptibility (χ in ppb referenced to CSF) and PiB-PET retention 
(SUVR) separated by APOE-e4 status within the two groups. * Significant difference between APOE-e4 
positive and negative with p < 0.05, ** p < 0.01, *** p < 0.001. d indicates effect sizes (Cohen's d). 
7.4.3 The combination of MCI with high iron-load is associated with altered MPFC-
coupling. 
The rs-fMRI functional connectivity analyses using MCI status and iron classification as covariates resulted 
in a mask consisting of 1502 voxels of significantly increased activation (p-FDR-corrected<0.001) with 
T(1,7) = 10.99. Main regions include frontal pole right (276 voxels, 3% of ROI), paracingulate gyrus left 
(188 voxels, 14%), frontal medial cortex (145 voxels, 15%), cingulate gyrus (146 voxels, 6%), frontal pole 
left (122 voxels, 2%) and paracingulate gyrus right (116 voxels, 9%), see also Figure 2. 
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Figure 2: Regions that show significant increased iron associated coupling (T(1,7) above 10.99 
indicating p-FDR-corrected<0.001) with the medial prefrontal cortex (MPFC) in subjects with MCI. 
7.4.4 Susceptibility and Aβ-plaque-load correlate within brain regions defined by altered 
MPFC-coupling. 
The mask of the region with significantly increased coupling was applied to the individual PiB-PET images 
and QSM maps of all MCI subjects (Figure 3). The Spearman’s correlation between cortical PiB-PET 
retention and susceptibility was found to be p<0.001 (Spearman’s rho=0.86, R2-adjusted=0.80). Analysis 
of the extracted values per group showed significant increases of cortical PiB-PET retention and 
susceptibility in the APOE-e4 carrier group of the MCI subjects (Figure 3). Moreover, in the MCI group, 
the odds ratio for an APOE-e4 carrier to have “high” PiB-PET retention was 48 (p<0.01, 95% confidence 
interval=2.6-932.8) and 17.5 (p<0.05, 95% confidence interval=2.2-250.3) to be “high” iron compared to 
a non-carrier.  
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Figure 3: Average Cortical PiB-PET Retention and Cortical Susceptibility of all MCI subjects (top) for 
the region with significantly increased coupling shown in Figure 2. The dotted line indicates the median 
split of the Cortical PiB-PET Retention of all subjects in the study, the trend line is indicated in gray 
(p<0.001, Spearman’s rho=0.86, R2-adjusted=0.80). Average Cortical PiB-PET Retention and Cortical 
Susceptibility for MCI subjects and controls when split based on APOE-e4 status (bottom), the error bars 
represent standard error. *** Significant difference between APOE-e4 positive and negative with 
p<0.001. 
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7.5 Discussion 
In this study magnetic susceptibility was used as a MRI-based measure of cerebral iron-load and combined 
with PiB-PET for measuring Aβ-plaque density in elderly subjects with normal cognition and MCI. For 
clarity and consistency with earlier studies, changes in susceptibility values will be referred to as changes 
in iron levels, due to the previously demonstrated correlation of susceptibility values with tissue iron levels 
in brain gray matter (Deistung, Schafer, et al. 2013; Lim et al. 2013; Langkammer et al. 2012; Schweser et 
al. 2012; Li, Wu, and Liu 2011). The main finding of our study is the characterization of brain regions 
affected by high iron in MCI, within which a spatial colocalization of Aβ-plaques and iron was observable. 
This effect was associated with increased genetic risk for AD-dementia. As this colocalization is consistent 
with neuropathologic accounts on AD-signature brain regions (Serrano-Pozo et al. 2011), our data may 
complement earlier considerations on the effect of cerebral iron on AD-risk (Ayton et al. 2015). To our 
knowledge this is the first report on a significant impact of iron on functional network integrity in subjects 
with MCI. 
Although a previous smaller QSM-study reported higher iron-load in AD (Acosta-Cabronero et al. 2013), 
our data does not show a general effect for MCI when compared to controls (Table 2) indicating such 
differences might occur in later stages of AD progression. However, MCI subjects with the APOE-e4 allele 
did show significantly higher iron levels in the neocortex (Table 3), which is a brain region significantly 
affected by AD-pathology at early stages of disease progression (Serrano-Pozo et al. 2011). Our finding of 
increased cortical iron may therefore support earlier considerations that MCI in APOE-e4 carriers may 
represent a prodromal stage of AD (Sperling et al. 2015). Increased cortical iron may be a more specific 
correlate of emerging neuro-cognitive dysfunction in prodromal AD than cortical Aβ-plaque-load, which 
was in our data associated with APOE-e4 independently from MCI (Table 3). This may be consistent with 
earlier data from MRI phase experiments that indicate significant change only for MCI subjects that 
progressed to dementia (Kirsch et al. 2009) and considerations on synergistic effects of Aβ and other aspects 
of neurodegeneration in AD (Jagust 2016; Mormino, Betensky, Hedden, Schultz, Amariglio, et al. 2014). 
The fact that reduced volume of subcortical nuclei including the hippocampal area was associated with MCI 
but not APOE-e4 most likely reflects heterogeneity of possible causes for MCI in the elderly. 
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It has been shown that the T2-prep BOLD method can achieve comparable contrast-to-noise ratio (CNR) 
as the conventional echo-planar-imaging (EPI) based BOLD approach, but has much reduced signal 
dropout and image distortion especially in brain regions close to air cavities such as some frontal and 
temporal areas (Donahue et al. 2010; Hua et al. 2011; Rane et al. 2015). Such dropout and distortion are 
particularly problematic at 7T where magnetic susceptibility gradients increase substantially at air-tissue 
boundary. At 3T or lower fields, where most clinical scans are conducted, such EPI artifacts are much 
reduced. Therefore, the T2-prep BOLD fMRI method in this study at 7T was adopted and it is expected 
that the findings are generalizable to studies using conventional EPI BOLD fMRI sequences at 3T. For this 
study a seed based approach investigating functional connectivity of the MPFC was chosen, as the MPFC 
is a central component of the DMN, which has been demonstrated to be impaired by Aβ pathology already 
in the preclinical stage of AD (Mintun et al. 2006). Our findings of iron-load being associated with increased 
coupling in fronto-temporal brain regions is consistent with earlier reports on DMN-change in AD (Agosta 
et al. 2012; Damoiseaux et al. 2012) and thus indicate that increased iron may contribute to the dysfunction 
of cognitive brain networks in subjects at risk for AD. However, as the current study investigated combined 
effects of MCI and iron-load for definition of a brain region with particular liability for AD-associated brain 
change based on altered coupling to the MPFC (Buckner et al. 2009), our data does not support an 
independent role of iron for augmenting pathological decline in AD. 
The reported correlation (Figure 3) between cortical iron and Aβ-plaque-load within these functionally 
altered brain regions suggest that increased cerebral iron relates to regional accumulation of Aβ in subjects 
at risk for AD and reflects preclinical neuronal dysfunction in AD-signature regions. Additionally, our 
finding of significantly higher levels of both iron and Aβ in APOE-e4 carriers is consistent with earlier 
reports and suggests that the APOE-e4 allele may confer susceptibility to AD via brain iron accumulation 
(Ayton et al. 2015).  
Our data furthermore suggest that the co-occurrence of iron and Aβ may be mediated by APOE-e4, which 
has been demonstrated to both promote cerebral Aβ accumulation by competing for the same clearance 
pathways (Verghese et al. 2013) and increase cerebral iron retention by impaired lipoprotein trafficking due 
to low affinity of APOE-e4 to high-density lipoprotein (Ayton et al. 2015). While direct interactions 
between iron and Aβ may result in increased toxicity by production of redox-active iron forms and oxidative 
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stress (Liu, Moloney, et al. 2011; Huang et al. 1999), brain iron accumulation is also associated with 
microglial over-activation (Zeineh et al. 2015), promoting neurodegeneration in AD (Mosher and Wyss-
Coray 2014). Our observation of altered functional connectivity, may reflect these processes and thus 
indicate preclinical brain change with the potential of causing progressive neuronal damage, as reflected by 
worsening neurocognitive disorder. Although the sample size is small, the increased sensitivity at the high 
field strength of 7T with inherently better SNR in QSM, provides currently the most sensitive detection of 
in vivo gray matter iron levels (Langkammer et al. 2012). When interpreting the current data it needs to be 
taken into account that the QSM-signal is biased by decreased myelin density (Langkammer et al. 2012; 
Liu, Li, et al. 2011). However, the cortical and deep gray matter regions investigated in this study are low 
in myelin content and thus the myelin contribution to the susceptibility signal in this study was considered 
negligible. While spatial co-localization of microhemorrhages with Aβ-plaques may bias iron measures 
(Dierksen et al. 2010), in the current study no microhemorrhages were observable within the brain regions 
investigated. 
Considering that iron may reflect processes associated with Aβ related neurocognitive dysfunction, further 
studies are needed to investigate whether the efficacy of therapeutic strategies lowering brain Aβ-plaque-
load for slowing down progression of AD (Nitsch and Hock 2008; Winblad et al. 2014), should be 
complemented by iron-targeted medication (Crapper McLachlan et al. 1991; Wood 2015). 
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8.1 Abstract 
The aging brain is characterized by an increased presence of neurodegenerative and vascular pathology. 
However, there is substantial variation regarding the relationship between an individual’s pathological 
burden and resulting cognitive impairment. To identify correlates of preserved cognitive functioning at 
highest age, the relationship between β-amyloid plaque-load, presence of small vessel cerebrovascular 
disease (SVCD), iron-burden and brain atrophy was investigated. 80 cognitively unimpaired participants 
(44 oldest-old, aged 85-96; 36 younger-old, aged 55-80) were scanned by integrated PET-MRI for assessing 
β-regional amyloid plaque-load (18F-Flutemetamol), white matter hyperintensities as an indicator of SVCD 
(FLAIR-MRI) and iron-load (Quantitative Susceptibility Mapping). For the oldest-old group, lower cortical 
volume, increased β-amyloid plaque-load, prevalence of SVCD and lower cognitive-performance in the 
normal range was found. However, compared to normal-old, cortical iron burden was lower in the oldest 
old. Moreover, only in the oldest-old, entorhinal cortex volume positively correlated with β-amyloid 
plaque-load. Our data thus indicate that the co-occurrence of aging-associated neuropathologies with 
reduced QSM-measures of cortical iron-load constitutes a lower vulnerability to cognitive loss.    
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8.2 Introduction 
While advanced age is associated with substantial brain change and increased risk for cognitive decline, 
several studies on populations of older adults have revealed high levels of cognitive functioning despite 
considerable brain pathology. The resilience against such pathologies can be described as the brain’s 
reserve; the cognitive and physiological properties that allow an individual to better tolerate age-related 
brain alterations and neuropathological burden before cognitive performance is impaired (Barulli and Stern 
2013). Alternatively, maintained cognitive functioning could be attributed not to reserve, but to the presence 
of neuroprotective factors such as genetic variants, or alterations in clearance mechanisms that prevent the 
accumulation of neuropathologies at high age (Nyberg et al. 2012). Individuals in the age-group of 85 years 
and above ("oldest-old") are of particular interest when investigating both the relationship between manifest 
brain change and risk for Alzheimer's disease (AD) (Kawas et al. 2013), and potential physiological factors 
that promote resistance against age-related neuropathological burden (Nyberg et al. 2012; Rogalski et al. 
2013). While Apolipoprotein E ε4 (APOE4) carrier-status is the strongest known risk factor for sporadic 
AD in the younger-old (Corder et al. 1993) and has been linked to increased β-amyloid plaque burden in 
the cognitively normal (Hollands et al. 2017), there also are reports suggesting no association of APOE4 
status with incident dementia or compensatory reserve mechanisms in the oldest-old (Corrada et al. 2013; 
Garibotto et al. 2012). 
Several studies have reported substantial discrepancies between measurable neuropathology and expected 
cognitive performance. This includes increased levels of β-amyloid plaques, which may reflect risk for 
future cognitive decline due to AD (Kawas et al. 2013; Sperling et al. 2009) and can be measured in 
cognitively healthy older adults (Mintun et al. 2006). In addition, regional atrophy was linked to AD-
associated neurodegenerative brain change, typically affecting hippocampus and entorhinal cortex years 
before manifestation of cognitive decline (de Leon et al. 1989; Frisoni et al. 2010). The coexistence of β-
amyloid plaques with other non-AD specific neurodegenerative alterations could indicate the greatest risk 
for progression to cognitive decline (Jagust 2016; Mormino, Betensky, Hedden, Schultz, Amariglio, et al. 
2014). For example, small-vessel cerebrovascular disease (SVCD) is a frequent finding in cognitively 
healthy older adults, and relates to pathogenic markers of AD including β-amyloid plaque burden and 
regional atrophy, thus increasing risk for cognitive dysfunction (Guzman et al. 2013). Cerebral 
accumulation of iron is another neuropathological finding associated with aging, but also with 
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neurodegenerative disorders including AD (Ayton et al. 2015; Ayton et al. 2017). Local iron accumulations 
in the vicinity of β-amyloid plaques may reflect both oxidative stress (Andersen, Johnsen, and Moos 2014; 
Meadowcroft et al. 2009; Rottkamp et al. 2001) and presence of activated microglia (Zeineh et al. 2015). 
Additionally, activated proinflammatory microglia have been correlated to β-amyloid associated 
neurodegeneration and cognitive impairment (Serrano-Pozo et al. 2016; Fan et al. 2017), suggesting that in 
vivo measures of iron could indicate both oxidative stress and β-amyloid associated neurodegeneration (van 
Bergen, Li, et al. 2016; Derry and Kent 2017; Ayton et al. 2017). While functional brain networks are 
altered at very early stages in AD and have been linked to Aβ-pathology (Buckner 2005; Sperling et al. 
2009; Koch et al. 2014; Quevenco et al. 2017), they are also considered to provide means for neural 
compensation for pathological brain change during aging (Franzmeier et al. 2017; Marques et al. 2016; 
Steffener and Stern 2012).  
State-of the art neuroimaging using multiple imaging modalities can provide in vivo information on various 
neuropathological burdens. Radioactive tracers may be used for measuring cerebral β-amyloid plaque 
burden by Positron-Emission-Tomography (PET) (Klunk et al. 2004; Vandenberghe et al. 2010). T1 
weighted MRI is an established measure for regional atrophy in AD (Frisoni et al. 2010) and SVCD severity 
can be inferred from white matter hyperintensities (WMH), as measured by Fluid-Attenuated Inversion 
Recovery (FLAIR) MRI (Guzman et al. 2013). Recent developments on quantitative susceptibility mapping 
(QSM) techniques (Deistung, Schafer, et al. 2013; Li, Wu, and Liu 2011; Lim et al. 2013; Schweser et al. 
2012) allow for in vivo measures of cerebral iron-load. Finally, functional connectivity (FC) measures can 
be assessed from BOLD functional MRI (fMRI) at rest and is an established measure of cognitive brain 
network integrity in a context of AD-pathology (Buckner 2005; Sperling et al. 2009; Koch et al. 2014).  
While research on oldest-old populations may significantly advance knowledge on both protective and risk 
factors in AD and other age-related cognitive disorders (Kawas et al. 2013), not much is known on 
mechanisms that determine the relationship between presence of major neuropathologies and preserved 
cognitive functioning in the oldest-old. Aims of the current study therefore were 1.) to assess prevalence of 
aging-related brain change in a population of cognitively healthy older adults by assessing cerebral β-
amyloid burden, differences in structural volume as an indicator of present neurodegenerative change, 
cerebral iron-load and the regional distribution of WMH as a proxy of SVCD; 2.) to characterize brain-
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physiology and neural mechanisms associated with preserved cognitive function, by assessing interactive 
relationships of pathological alterations and differences between cognitively healthy oldest-old and 
younger-old. 
8.3 Methods 
8.3.1 Participants 
For the current study, two cohorts at the Hospital for Psychogeriatric Medicine and Institute for 
Regenerative Medicine (IREM), University of Zurich (UZH), Switzerland were combined resulting in a 
total sample of 80 healthy and cognitively unimpaired older adults. Within the recruited sample, two groups 
were compared: 36 "younger-old" (ages 55-80 years) and 44 "oldest-old" (ages 85-96 years) participants. 
Study procedures were in concordance with Human Research Act of Switzerland as well as with the 
declaration of Helsinki. Written informed consent was obtained from all participants before inclusion in the 
study. 
Inclusion criteria were: preserved everyday functioning and no significant cognitive impairment, as 
assessed by the CERAD neuropsychological battery (Sotaniemi et al. 2012) and additional tests used in 
earlier studies of ours (van Bergen, Li, et al. 2016), including Mini Mental State Examination (MMSE), 
Verbal Learning and Memory Test (VLMT), Boston Naming Test (BNT), Trail Making Test B/A, and 
Stroop inference test. Exclusion criteria included: significant medication or drug abuse with possible effects 
on cognition, inability to partake MRI, MRI scans with the evidence of infection or infarction, clinically 
relevant changes in red blood cell count, serious medical or neuropsychiatric illness and significant 
exposure to radiation. 
8.3.2 MRI data acquisition 
All participants were scanned using a 3T GE SIGNA PET-MR whole-body scanner (GE Medical Systems, 
Milwaukee, WI, USA) equipped with an 8-channel head coil. T1-weighted BRAVO images (TI=450ms, 
voxel size=1x1x1mm3, flip-angle=12°, ASSET factor=2, scan time=6:00min) were acquired for 
anatomical referencing and automated image segmentation. MR phase measurements used for QSM 
calculation were acquired using a multi-echo 3D gradient recalled echo (GRE) sequence with 6 echoes 
(TR/TE1/ΔTE=40/6/4ms, voxel size=1x1x1mm3, flip angle=15°, bandwidth=±62.5 kHz, flow 
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compensated, ASSET factor=2, scan time=7:53min). Phase data acquired with an echo time in the range of 
18-26ms was used for QSM reconstruction. Images used to determine WMH were acquired using a CUBE 
FLAIR sequence (TR=6500ms, TE=134, ARC factor=2, voxel size=1x1x1.2mm3, bandwidth=±31.25 kHz, 
scan time=6:07min). fMRI for the oldest-old was acquired at rest using a standard gradient echo EPI 
sequence (TR=2547ms, TE=13.8ms, voxel size=3x3x3mm3, flip angle=90°, ARC factor=2, 
duration=8:42min). fMRI as part of the study-protocol for the normal-old population was acquired 
separately with identical settings using a 3T GE SIGNA 750w whole-body scanner with a 32-channel head 
coil, as differences in head-coil channel-number have been demonstrated earlier to not significantly affect 
measured resting-state network connectivity (Paolini et al. 2015).  
8.3.3 Assessment of structure volumes 
To assess regional differences, the T1-weighted image was segmented using a multi-atlas matching 
approach consisting of 143 Regions of Interest (ROIs) developed as part of the Johns Hopkins University 
brain atlas. The atlas system is optimized for the parcellation of potential non-healthy brains by applying a 
Multiple-Atlas Likelihood Fusion algorithm and Ontology Level Control technology on the JHU multi-
atlas sets (Djamanakova et al. 2014; Tang et al. 2013; Mori et al. 2016). Specifically, the atlas set of 26 
participants aged between 50 and 90 years was used.  
To normalize different brain sizes across participants, individual structural volume was corrected with the 
following approach: Corrected structure volume = Original structure volume × (whole sample mean 
intracranial volume / participant intracranial volume) (van Bergen, Li, et al. 2016). Twelve gray-matter 
ROIs were selected based on earlier reports on distribution of brain pathology at early stages of AD (Frisoni 
et al. 2010; Serrano-Pozo et al. 2011). 
ROI-masks were eroded with two pixels to account for partial volume effects before being used as a mask 
to analyze average iron-load (QSM), β-amyloid burden and WMH detection. These imaging volumes were 
first re-sliced to the individual’s T1 space, in which the atlas was defined, before further analysis. 
8.3.4 Quantitative susceptibility mapping (QSM) for measuring brain iron-load 
Multiple processing steps were performed to calculate from the acquired MR phase images the quantitative 
susceptibility maps of which local cerebral iron-load was assessed. First, phase unwrapping was performed 
using Laplacian based phase unwrapping (Li, Wu, and Liu 2011). A brain mask was then obtained by skull-
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stripping the GRE magnitude image acquired at TE of 14ms using FSL's brain extraction tool (BET, FMRIB 
Oxford, UK). The unwrapped phase images were then divided by 2π*TE to obtain an image of the 
frequency shift in Hz for each echo. Subsequently, background fields were eliminated with the sophisticated 
harmonic artifact reduction for phase data (SHARP) (Schweser et al. 2011) approach using a variable 
spherical kernel size with a maximum radius of 4mm and a regularization parameter of 0.05 (Schweser et 
al. 2011; Wu, Li, Guidon, et al. 2012). After removal of background fields, the resulting images of the three 
echoes were averaged to obtain a higher SNR as compared to single echo reconstruction (Wu, Li, Avram, 
et al. 2012). Inverse dipole calculations to obtain the susceptibility maps were performed using an iLSQR 
based minimization (Li et al. 2015). The means of the standard deviations of susceptibility in commonly 
accepted QSM reference regions, such as various white matter bundles and sections of the cerebrospinal 
fluid, were evaluated to select the region with the lowest mean standard deviations as the reference region 
(Deistung, Schafer, et al. 2013). For clarity and consistency with earlier studies, changes in susceptibility 
values will be referred to as changes in iron-load, due to the previously demonstrated correlation of 
susceptibility values with tissue iron-load in brain gray matter (Deistung, Schafer, et al. 2013; Li, Wu, and 
Liu 2011; Lim et al. 2013; Schweser et al. 2012). 
8.3.5 Flutemetamol-PET for estimation of brain β-amyloid plaque burden 
Flutemetamol-PET was used to estimate individual local brain β-amyloid plaque burden (Vandenberghe et 
al. 2010). Individual dose of 140MBq of Flutemetamol was injected into the cubital vein. Time-of-flight 
algorithm including necessary corrections were applied to reconstruct the PET-images. Standard MRAC 
images were used to derive attenuation correction maps according standard implemented algorithms. Late 
frame (minutes 85-105) values were standardized by the cerebellar gray matter value (Vandenberghe et al. 
2010), resulting in 3D-volumes of Flutemetamol retention as an estimate of β-amyloid burden via standard 
uptake value ratios (SUVR) (matrix=256x256x89, voxel size=1.2x1.2x2.78mm3).  
Single measures of individual cortical β-amyloid burden and iron-load were calculated for each participant 
based on average gray-matter ROI values of Flutemetamol-SUVR and susceptibility, respectively, as 
reported earlier (van Bergen, Li, et al. 2016). To determine "amyloid-positive" status the Flutemetamol-
SUVR cutoff value of 1.562 was used (Vandenberghe et al. 2010). 
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8.3.6 Assessment of SVCD by semi-automated WMH detection 
To assess general occurrence of WMH, each participant’s FLAIR images were segmented into gray matter 
and major white matter regions using the previously generated atlas. The WMH in each white matter region 
were automatically identified by segmenting and grouping voxels with intensities 1.5 standard deviation 
above the average gray matter intensity of each participant (Iorio et al. 2013). Automatically segmented 
regions were then manually validated, for example to only count a WMH in one region when it extended 
with a small number of voxels into a second white matter region. The SVCD-burden was inferred on by 
summing the number of regions exhibiting WMH.  
8.3.7 Local correlation analysis 
For each of the selected ROIs, WMH score and regional volume were used as outcome variables with local 
β-amyloid burden and local iron-load as predictors, while controlling for age and gender. To investigate 
differences in the correlation effects between oldest-old and younger-old, Fisher’s r-to-z transformation 
was applied on the correlation coefficients within each region for each group (Fisher 1921). False Discovery 
Rate (FDR) correction for multiple testing (Benjamini and Hochberg 1995) was applied to the p-values of 
all regions for each predictor-outcome pair and results were found significant when p-FDR-corrected < 
0.05. All statistical tests were performed in MATLAB R2016b (Mathworks, Natick, MA). 
8.3.8 Functional connectivity analysis 
Pre-processing of fMRI data was performed using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). To 
investigate differences in FC between oldest-old versus normal-old and the respective effects of Aβ-plaque-
density, iron-load and SVCD on oldest-old versus normal-old status, these measures were used as covariates 
in group level covariate analysis of seed-to-voxel FC of the medial prefrontal cortex (MPFC) and posterior 
cingulate cortex (PCC) region using the CONN-toolbox (Whitfield-Gabrieli and Nieto-Castanon 2012) 
(p<0.001, cluster threshold p-FDR-corrected<0.05). The signal was filtered with a band-pass filter (0.008–
0.09 Hz). Motion parameters, cerebrospinal fluid, and white matter were regressed out as variables of no 
interest.   
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8.4 Results 
8.4.1 Characteristics of the studied populations and neuropsychological performance.  
Demographic information for the investigated study populations and neuropsychological test performance 
at time of inclusion are summarized in table 1. The average education level, as measured by years of formal 
education, was significantly lower in oldest-old compared to younger-old (oldest-old: 14.2 (2.8) years; 
younger-old: 15.9 (2.6), p=0.010). Clinical examination revealed self-reliance and absence of cognitive 
impairment in the oldest-old group. However, they performed significantly lower than the younger-old 
group in all administered neuropsychological tests except CERAD word list recognition (table 1B). Eleven 
out of 36 younger-old (31%) and six out of 44 oldest-old (14%) were APOE4 carriers. Fisher test on the 
odds ratio of an APOE4 carrier having oldest-old status resulted in a non-significant trend (p=0.071, 
CI=0.11-1.09). 
 Whole sample Younger-old Oldest-old 
A) Demographics    
N (M/F) 80 (54/26) 36 (21/15) 44 (33/11) 
Age 79.20 ± 11.80 67.75 ± 7.75 88.57 ± 2.69 ** 
Education 14.99 ± 2.85 15.92 ± 2.61 14.23 ± 2.84 ** 
ApoE-e4 carriers (%) 17 (21%) 11 (31%) 6 (14%) 
    
B) Neuropsychology    
MMSE 28.99 ± 1.10 29.44 ± 0.81 28.60 ± 1.17 ** 
VLMT: delayed recall 7.93 ± 3.99 8.58 ± 3.93 7.43 ± 4.02 ** 
Boston Naming Test 14.43 ± 0.77 14.73 ± 0.45 14.21 ± 0.89 ** 
Trail making test B/A 2.61 ± 1.41 2.17 ± 0.70 2.98 ± 1.71 ** 
CERAD: Word list recall 6.99 ± 1.93 7.79 ± 1.32 6.36 ± 2.12 ** 
CERAD: Word list recognition 9.77 ± 0.65 9.76 ± 0.61 9.78 ± 0.69 
CERAD: Word list learning 8.23 ± 1.39 8.82 ± 0.98 7.76 ± 1.49 ** 
CERAD: Fluency 21.54 ± 6.91 24.36 ± 5.61 19.37 ± 7.08 ** 
Stroop Interference: color-word 32.60 ± 11.26 27.91 ± 7.50 36.48 ± 12.40 ** 
Table 1: Overview of sample A) demographics and B) neuropsychological test performance measures as 
mean ± STD. * = significant difference (two-sample T-test) between the oldest-old and younger-old with 
p < 0.05, ** = p < 0.01 and *** = p < 0.001.  
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8.4.2 Prevalence of neuropathological burden in oldest- versus younger-old. 
While corrected structure volume in cortical gray matter regions and the hippocampus was significantly 
lower in oldest-old compared to younger-old, no significant difference could be observed for the entorhinal 
cortex (figure 1A, table 2A). The cutoff for Flutemetamol SUVR (Vandenberghe et al. 2010) identified 
eight oldest-old and five younger-old participants as "amyloid-positive". Consistently, quantitative 
assessment of Flutemetamol SUVR indicated significantly higher regional β-amyloid plaque burden in the 
oldest-old than younger-old for all twelve investigated brain structures (figure 1B, table 2B). Deep frontal 
white matter was found to have the lowest average susceptibility standard deviations and was selected as a 
reference region to assess relative iron-load for each participant. Interestingly, iron-load in the oldest-old 
was significantly lower in neocortical regions, insula and posterior cingulate. Only in the putamen was iron-
load higher in oldest-old than the younger-old (figure 2, table 2C). Almost all oldest-old exhibited 
substantial SVCD upon visual inspection, which is reflected by significantly higher (p=0.0002) SVCD in 
oldest-old (6.59 ± 0.62) compared to younger-old (2.36 ± 0.29, table 2C). For assessment of effects 
accountable to age, a 1-way MANCOVA with age as covariate was used to compare neuropsychological 
test scores, volume, cortical β-amyloid burden, cortical iron and SVCD between oldest-old and younger-
old. Here, a significant effect after correction for age could only be observed for prevalence of SVCD 
(p=0.034, t=4.670).  
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Figure 1: Mean regional average values (SEM) per group for A) volume (ml), B) β-amyloid plaque 
burden (18F-Flutemetamol SUVR). Significant differences after FDR-multiple-testing-correction are 
indicated by * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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Figure 2A) Mean regional average values (SEM) per group for iron (susceptibility, ppm). Significant 
differences after FDR multiple testing correction are indicated by * = p < 0.05, ** = p < 0.01 and *** = 
p < 0.001. 2B) Scatterplot for correlations between entorhinal volume (ml) and entorhinal Aβ-plaque-
density for oldest-old (r=0.39, p=0.01), normal-old r=-0.09, p=0.59. 2C) Main effects for regional 
differences in FC between oldest-old and normal-old as measured using the MPFC and PCC (only 
overlaid T(1,80) > 3.41, indicating p < 0.001) (2D).  
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 Statistics, correlation analysis 
 
β-amyloid plaque 
burden Iron-load 
A) Regional volume   
Amygdala p=0.01   r=0.28 * p=0.94   r=-0.03 
Insula p=0.99   r=0.00 † p=0.02   r=0.28 * 
Hippocampus p=0.55   r=-0.08 p=0.74   r=0.06 
Entorhinal Cortex p=0.08   r=0.21 † p=0.01   r=-0.30 * 
Frontal Cortex p=0.99   r=0.00 p=0.54   r=0.09 
Temporal Cortex p=0.34   r=0.12 p=0.10   r=0.19 
Parietal Cortex p=0.18   r=-0.16 p=0.03   r=0.26 * 
Occipital Cortex p=0.99   r=-0.02 p=0.68   r=0.06 
Neocortex p=0.90   r=-0.04 p=0.11   r=0.19 
   
B) SVCD (WMH-scores) 
Amygdala p=0.06   r=0.22 p=0.07   r=-0.22 
Insula p=0.07   r=0.22 p=0.42   r=-0.12 
Hippocampus p=0.99   r=0.01 p=0.98   r=0.04 
Entorhinal Cortex p=0.05   r=0.23 * p=0.05   r=-0.24 * 
Frontal Cortex p=0.05   r=0.23 * p=0.06   r=-0.23 
Temporal Cortex p=0.17   r=0.17 p=0.03   r=-0.26 * 
Parietal Cortex p=0.23   r=0.16 p=0.01   r=-0.29 * 
Occipital Cortex p=0.48   r=0.11 p=0.12   r=-0.19 
Neocortex p=0.11   r=0.20 p=0.03   r=-0.26 * 
Table 2: Regional correlation analysis for A) volume and B) SVCD with the respective local β-amyloid 
plaque burden and iron-load. Indicated are values for the entire sample (n=80), * indicates a significant 
correlation with p-FDR-corrected < 0.05; † = significant differences in regressions slopes between 
oldest-old and younger-old using Fisher r-to-z transformation, with p < 0.05. 
 
 Statistics, pathology-measures by group 
 
Whole sample Younger-old Oldest-old 
A) Volume (ml) 
Amygdala 3.19 ± 0.04 3.24 ± 0.05 3.14 ± 0.05 
Insula 11.83 ± 0.12 12.32 ± 0.15 11.44 ± 0.16 *** 
Hippocampus 6.61 ± 0.07 6.95 ± 0.08 6.34 ± 0.08 *** 
Entorhinal Cortex 1.74 ± 0.02 1.72 ± 0.04 1.76 ± 0.03 
Post Cingulate 13.97 ± 0.12 14.18 ± 0.20 13.81 ± 0.15 
Thalamus 8.63 ± 0.08 9.04 ± 0.09 8.29 ± 0.10 *** 
Caudate 6.70 ± 0.08 6.77 ± 0.13 6.65 ± 0.11 
Putamen 6.65 ± 0.07 6.91 ± 0.09 6.44 ± 0.10 ** 
Globus Pallidus 2.46 ± 0.03 2.56 ± 0.04 2.38 ± 0.03 *** 
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Frontal Cortex 146.07 ± 0.78 148.31 ± 1.16 144.24 ± 0.97 * 
Temporal Cortex 111.56 ± 0.76 114.40 ± 1.02 109.24 ± 0.97 *** 
Parietal Cortex 76.37 ± 0.45 77.64 ± 0.51 75.33 ± 0.66 * 
B) β-amyloid plaque burden (18F-Flutemetamol SUVR) 
Amygdala 1.37 ± 0.02 1.24 ± 0.02 1.47 ± 0.03 *** 
Insula 1.38 ± 0.04 1.21 ± 0.03 1.52 ± 0.07 *** 
Hippocampus 1.35 ± 0.02 1.28 ± 0.02 1.40 ± 0.03 ** 
Entorhinal Cortex 1.18 ± 0.02 1.08 ± 0.02 1.26 ± 0.03 *** 
Post Cingulate 1.46 ± 0.05 1.31 ± 0.04 1.59 ± 0.08 ** 
Thalamus 1.77 ± 0.03 1.63 ± 0.03 1.88 ± 0.05 *** 
Caudate 1.21 ± 0.04 1.10 ± 0.04 1.30 ± 0.07 * 
Putamen 1.65 ± 0.04 1.47 ± 0.03 1.79 ± 0.06 *** 
Globus Pallidus 2.35 ± 0.04 2.20 ± 0.04 2.48 ± 0.05 *** 
Frontal Cortex 1.32 ± 0.04 1.17 ± 0.04 1.45 ± 0.07 ** 
Temporal Cortex 1.29 ± 0.03 1.17 ± 0.02 1.38 ± 0.05 ** 
Parietal Cortex 1.27 ± 0.04 1.20 ± 0.03 1.33 ± 0.06 
Neocortex 1.30 ± 0.03 1.19 ± 0.03 1.39 ± 0.06 ** 
C) Iron-load (susceptibility, ppm) 
Amygdala 0.022 ± 0.001 0.024 ± 0.002 0.021 ± 0.002 
Insula 0.009 ± 0.001 0.013 ± 0.001 0.005 ± 0.001 *** 
Hippocampus 0.018 ± 0.001 0.018 ± 0.002 0.018 ± 0.001 
Entorhinal Cortex 0.049 ± 0.002 0.050 ± 0.002 0.048 ± 0.003 
Post Cingulate 0.021 ± 0.001 0.023 ± 0.001 0.019 ± 0.001 ** 
Thalamus 0.018 ± 0.001 0.018 ± 0.001 0.018 ± 0.002 
Caudate 0.074 ± 0.003 0.076 ± 0.003 0.073 ± 0.005 
Putamen 0.088 ± 0.004 0.079 ± 0.002 0.096 ± 0.006 * 
Globus Pallidus 0.130 ± 0.004 0.134 ± 0.003 0.128 ± 0.006 
Frontal Cortex 0.023 ± 0.001 0.025 ± 0.001 0.022 ± 0.001 * 
Temporal Cortex 0.021 ± 0.001 0.023 ± 0.001 0.019 ± 0.001 * 
Parietal Cortex 0.026 ± 0.001 0.028 ± 0.001 0.024 ± 0.001 ** 
D) SVCD-burden (WMH regions identified) 
Whole brain 4.69 ± 1.80 2.36 ± 0.29 6.59 ± 0.62 *** 
Table 3: Overview of average structure volume, β-amyloid plaque burden, iron-load and WHM scores 
per region and group (mean ± SEM). Group-differences were investigated by independent-sample, two 
tailed T-test and FDR correction for multiple testing * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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8.4.3 Relationship between β-amyloid burden, iron-load, structure volume and prevalence 
of SVCD. 
Significant correlations (p-FDR-corrected<0.05) in the whole sample were found between β-amyloid 
burden and structure volume in the amygdala; and between iron-load and structure volume in insula, 
entorhinal cortex and parietal cortex (table 3A). Prevalence of SVCD correlated with β-amyloid burden in 
the entorhinal cortex and frontal cortex. Moreover, SVCD correlated negatively with iron-load in the 
amygdala, entorhinal cortex, parietal cortex and the neocortex as a whole (table 3B). When testing APOE4 
carriers separately, significant correlations between β-amyloid burden and SVCD (p=0.01 r=0.80) and iron-
load and volume (p=0.02 r=-0.60) could be observed in the entorhinal cortex. 
8.4.4 Group-specific correlations of structure volume with β-amyloid burden. 
Secondary, group specific regression-analysis indicated a significant correlation of high local β-amyloid 
burden with high structure volume in the entorhinal cortex of the oldest-old, which was not present in the 
younger-old (figure 2B, oldest-old p=0.01 r=0.39, younger-old p=0.59 r=-0.09) and insula (oldest-old 
p=0.04 r=0.31, younger-old p=0.31 r=-0.18), significant difference of correlations was confirmed by 
Fisher’s r-to-z transformation (entorhinal cortex p=0.031, insula p=0.032). 
To identify potential effects of education level, correlation analysis was performed with local structure 
volume and local β-amyloid burden as outcome variables and years of education as predictor, while 
controlling for age and gender. No significant correlation with years of education was found in any of the 
structures (table 4). 
 
Whole sample Younger-old Oldest-old 
A) Volume (ml)    
Amygdala p=0.09   r=-0.21 p=0.68   r=-0.15 p=0.62   r=-0.14 
Insula p=0.15   r=-0.19 p=0.99   r=0.04 p=0.52   r=-0.16 
Hippocampus p=0.29   r=-0.15 p=0.09   r=-0.21 p=0.94   r=0.09 
Entorhinal Cortex p=0.07   r=-0.21 p=0.55   r=-0.17 p=0.92   r=-0.09 
Post Cingulate p=0.19   r=-0.18 p=0.99   r=0.08 p=0.35   r=-0.19 
Thalamus p=0.33   r=-0.15 p=0.92   r=0.11 p=0.83   r=-0.11 
Caudate p=0.16   r=-0.19 p=0.99   r=0.00 p=0.32   r=-0.20 
Putamen p=0.23   r=-0.17 p=0.66   r=0.15 p=0.55   r=-0.15 
Globus Pallidus p=0.25   r=-0.16 p=0.99   r=-0.07 p=0.99   r=-0.04 
Frontal Cortex p=0.14   r=-0.20 p=0.99   r=0.01 p=0.42   r=-0.18 
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Temporal Cortex p=0.15   r=-0.19 p=0.99   r=0.01 p=0.46   r=-0.17 
Parietal Cortex p=0.19   r=-0.18 p=0.99   r=0.02 p=0.28   r=-0.21 
Neocortex p=0.13   r=-0.20 p=0.99   r=-0.02 p=0.40   r=-0.18 
B) β-amyloid plaque burden (18F-Flutemetamol SUVR) 
Amygdala p=0.99   r=0.03 p=0.90   r=-0.11 p=0.99   r=0.04 
Insula p=0.68   r=0.10 p=0.99   r=-0.06 p=0.99   r=-0.03 
Hippocampus p=0.99   r=0.04 p=0.86   r=-0.11 p=0.36   r=-0.19 
Entorhinal Cortex p=0.50   r=0.12 p=0.09   r=0.13 p=0.99   r=0.00 
Post Cingulate p=0.12   r=0.20 p=0.52   r=0.18 p=0.60   r=0.14 
Thalamus p=0.43   r=0.13 p=0.17   r=-0.21 p=0.83   r=0.11 
Caudate p=0.99   r=0.04 p=0.70   r=-0.14 p=0.66   r=0.13 
Putamen p=0.27   r=0.16 p=0.99   r=0.08 p=0.99   r=0.03 
Globus Pallidus p=0.45   r=0.13 p=0.99   r=0.01 p=0.99   r=0.00 
Frontal Cortex p=0.28   r=0.16 p=0.99   r=0.03 p=0.86   r=0.10 
Temporal Cortex p=0.38   r=0.14 p=0.57   r=0.16 p=0.92   r=-0.10 
Parietal Cortex p=0.99   r=0.06 p=0.99   r=0.08 p=0.88   r=-0.10 
Neocortex p=0.17   r=0.19 p=0.59   r=0.16 p=0.74   r=-0.12 
Table 4: Regional correlation between years of education and A) structure volume and B) local β-
amyloid plaque burden. 
8.4.5 Functional connectivity analysis for group-differences and impact of 
neuropathological burden. 
Significantly different connectivity patterns (p<0.001, cluster threshold p-FDR-corrected<0.05) were 
observed for the MPFC (18277 voxels) and PCC (12592 voxels), by seed-based, voxel-wise comparison of 
BOLD-synchronicity at rest of the normal- versus oldest-old group, allowing for both increased ("positive 
differences") and decreased connectivity ("negative differences"). For the MPFC seed, positive differences 
for a network comprising mainly cingulate gyrus, frontal pole, frontal gyrus, occipital gyrus and temporal 
pole regions, and negative differences for a network comprising mainly hippocampus, cerebellum and parts 
of the temporal gyrus resulted (figure 2C). Analysis of connectivity with the PCC seed indicated a network 
with positive differences in postcentral gyrus and precuneus, and negative differences in the precentral 
gyrus, cingulate gyrus and frontal gyrus (figure 2D). By separately adding covariates of the per-subject 
measures of neuropathological burden to the connectivity-term, a substantial share of total variance of FC 
difference between normal- and oldest-old could be explained (MPFC: 90.3%; PCC: 59.6%). The 
respective contributions of the included neuropathological measures to the model are indicated in table 5.  
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 A) MPFC:  B) PCC: 
 Voxels Explained % of Main Effect  Voxels Explained 
% of Main 
Effect 
      
Main effect 18277 100%  12592 100% 
Only Aβ-plaque-density 5303 29.0%  5741 45.6% 
Only Iron-load 10441 57.1%  2313 18.4% 
Only SVCD 14160 77.5%  6092 48.4% 
Iron-load & SVCD 16100 88.1%  5305 42.1% 
Aβ-plaque-density & 
SVCD 
16082 88.0%  7315 58.0% 
Aβ-plaque-density & Iron-
load 
13703 75.0%  5627 44.7% 
Aβ-plaque-density & Iron-
load & SVCD 
16506 90.3%  7507 59.6% 
      
Table 5: Seed based analysis using A) MPFC and B) PCC for functional connectivity differences between 
oldest-old and normal-old, allowing for effects (% of main effect) attributable to the covariates cortical 
Aβ-plaque-density, cortical iron-load and SVCD-burden. (p<0.001, cluster threshold p-FDR-
corrected<0.05). The Main Effect for both MPFC and PCC is visualized in Figure 2. 
8.5 Discussion 
By investigating a study population of cognitively unimpaired younger- and oldest-old by combined PET-
MRI, we found significantly higher prevalence of neuropathological burden in the oldest-old, as reflected 
by cerebral β-amyloid burden, reduced volume of structures and higher prevalence of SVCD. While 
neuropsychological testing indicated generally lower performance levels in the oldest-old, they did not 
show significant cognitive impairment. Differences in the oldest-old furthermore included lower iron-load 
in cortical regions and an association of high entorhinal volume with entorhinal β-amyloid burden. Our 
findings support earlier considerations that distinct physiological brain properties may allow for maintained 
high cognitive functioning in the oldest-old, despite present brain pathology (Barulli and Stern 2013; 
Nyberg et al. 2012). To our knowledge, this is the first report indicating that reduced QSM measures of 
cortical iron-load constitute a lower vulnerability to loss of cognitive function at highest age.  
amyloid-PET tracers, such as 18F-Flutemetamol (Vandenberghe et al. 2010), have become an established 
approach to estimate regional β-amyloid burden in AD-risk populations. Differences in brain structure 
volumes were investigated by applying a multi-atlas matching approach to T1-MRI data, using Likelihood 
Fusion and Ontology Level Control algorithms, as validated for both healthy and diseased study populations 
(Djamanakova et al. 2014; Tang et al. 2013). Recent efforts in validation of the QSM technology made it 
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possible to quantitatively assess regional iron-load in vivo (Deistung, Schafer, et al. 2013; Langkammer et 
al. 2012) and assess iron in a context of neurodegenerative disease (van Bergen, Li, et al. 2016; van Bergen, 
Hua, et al. 2016; Acosta-Cabronero et al. 2013; Ayton et al. 2017). When interpreting the susceptibility 
data, it needs to be considered that the iron-load could vary on an inter-voxel basis and that QSM is biased 
by decreased myelin density (Langkammer et al. 2012; Liu, Li, et al. 2011). However, the cortical and deep 
gray matter regions investigated in this study are low in myelin content and thus the myelin contribution 
was considered minimal. FC analysis is a widely-used approach for assessing integrity of brain networks 
in a context of AD-risk and Aβ- pathology (Buckner 2005; Sperling et al. 2009; Koch et al. 2014). Distortion 
by processes of co-registration of PET with MR-indicators of neuropathological burden or bias due to 
changes occurring in the time between PET and MR acquisition could be avoided as the respective measures 
were acquired using an integrated PET-MR instrument. 
When investigating the entire study sample, a significant relationship between β-amyloid burden and 
reduced volume resulted, which appears consistent with earlier reports on biomarker-associations in 
populations of older adults at risk for AD (Frisoni et al. 2010; Mormino, Betensky, Hedden, Schultz, 
Amariglio, et al. 2014). Our observation of SVCD correlating with β-amyloid burden concurs with earlier 
ADNI-findings (Guzman et al. 2013). Interestingly, we find negative correlations between iron and SVCD 
throughout the brain - which surprised us, as we expected SVCD to be associated with paramagnetic 
properties due to extravasated hemoglobin and vascular pathology. Our SVCD measure did not include the 
size but only the occurrence of WMH as a reflection of incidence of vascular breakdown. This limitation 
could affect the validity of the measure and as such the results at this point are only indicative. Additional 
studies are needed to validate the use of this score and investigate underlying effects of SVCD on iron, 
including the potential role of activated microglia and other iron clearing mechanisms in the cognitively 
healthy older adults with SVCD. Our finding of substantial neuropathological burden in the oldest-old is 
consistent with earlier studies on high aged populations (Kawas et al. 2013). In general, reduced structural 
volume and increased β-amyloid burden were more pronounced in the oldest-old than in the younger-old, 
in line with earlier findings of reduced volume as an indicator of incipient neurodegeneration and cognitive 
decline (Frisoni et al. 2010; Mormino, Betensky, Hedden, Schultz, Amariglio, et al. 2014; Dekhtyar et al. 
2017). The oldest-old population in our study showed a generally lower cognitive performance than the 
younger-old, which appears consistent with earlier reports on non-pathological cognitive change during 
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aging. Oldest-old status in our sample was associated with fewer years of formal education, which reflects 
the lower availability of higher-education in Switzerland during adolescence of the very old participants. It 
is not expected that formal education influence results at this stage of their life, this is supported by the lack 
of correlation between years of education and β-amyloid burden or structure volume. Additionally, we only 
found a non-significant trend regarding the effect of APOE4 status for the odds of being oldest-old versus 
younger-old. This finding could be due to insufficient power in our sample. Alternatively, it might be 
consistent with earlier reports that suggest other factors of brain physiology beyond APOE4 determine 
cognitive functioning at a very high age (Corrada et al. 2013; Garibotto et al. 2012). The fact that our oldest-
old population exhibited a high degree of cognitive functionality despite present neuropathology concurs 
with earlier observations of preserved cognition at highest age (Nyberg et al. 2012; Rogalski et al. 2013). 
Considering the well-established relationship between high β-amyloid burden and risk for cognitive decline 
during aging (Jansen et al. 2015), our finding of significantly higher β-amyloid burden in cognitively 
unimpaired oldest-old participants suggests particular resilience against neuropathology. Here, our findings 
of lower iron-load in brain regions implicated in cognitive processes, such as the neocortex, posterior 
cingulate and insula, potentially reflect less neuronal damage. Pathological processes that are considered to 
be reflected by increased local iron-load include oxidative stress and presence of activated microglia 
(Meadowcroft et al. 2009; Nunez et al. 2012; Rottkamp et al. 2001; Zeineh et al. 2015; Serrano-Pozo et al. 
2016). Moreover, increased iron-load is a frequent finding in neurodegenerative disease (Andersen, 
Johnsen, and Moos 2014; Kruer 2013). Increased iron-load in basal ganglia structures, particularly the 
putamen, are a known effect of aging (Hallgren and Sourander 1958; Bartzokis et al. 1997) and are 
consistent with the spatial distribution of our QSM measures of local iron-load. Our observation of low 
cortical iron-load in the cognitively unimpaired oldest-old might thus reflect lower vulnerability to age-
related neuropathology, and may be consistent with reports of elevated brain iron being associated with 
mild cognitive impairment and liability for AD (van Bergen, Li, et al. 2016; Ayton et al. 2015; Ayton et al. 
2017; Derry and Kent 2017). Furthermore, our findings are consistent with recently published data on a 
relationship between increased QSM measures of cerebral iron and β-amyloid associated cognitive decline 
(Ayton et al. 2017). 
Several studies have investigated changes to the entorhinal cortex associated with aging and incipient AD, 
as indicated by reduced structural volume (de Leon et al. 1989; Frisoni et al. 2010), and found that increased 
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structural volume of memory regions promotes maintained cognitive performance (Dekhtyar et al. 2017; 
deToledo-Morrell et al. 2004). Thus, while the current clinical study does not provide information on 
neurobiological mechanisms, the here reported positive relationship between entorhinal structural volume 
and β-amyloid plaque-density, which was only observable in the oldest-old, might indicate lower 
vulnerability. However, as entorhinal cortex volumes in the oldest-old did not differ from the younger-old, 
this finding needs to be interpreted with caution. 
Finally, we found a significant difference in FC between oldest- and normal-old, observable for both the 
MPFC- and PCC-seed, which both serve as central hubs in cognition-related brain network activity. Our 
observations in cognitively healthy elderly appear consistent with earlier reports on regional extent of AD-
related network changes (Buckner 2005; Sperling et al. 2009) and furthermore indicate distinct neural 
adaptation to accumulating Aβ-plaque-density, SVCD and iron-load. 
Taken together, by investigating a cross-sectional sample of younger- and oldest-old, we 
provide neuroimaging-evidence that low cortical iron-load and high entorhinal volume despite high β-
amyloid burden might characterize individuals less affected by aging-associated neuropathologies. 
Additional translational studies are needed to characterize the interplay between molecular mechanisms 
and genetic disposition that allows for maintained cognitive function at highest age. While our findings are 
consistent with recent reports on low iron burden as a predictor of preserved cognitive functioning in older 
adults (Ayton et al. 2017), therapeutic trials are needed to investigate whether these correlates of individual 
resilience may be exploited for specific disease modifying intervention.  
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9.1 Abstract 
The accumulation of β-amyloid plaques is a hallmark of Alzheimer's disease (AD), and recently published 
data suggest that increased brain iron burden may reflect pathologies that synergistically contribute to the 
development of cognitive dysfunction. While preclinical disease stages are considered most promising for 
therapeutic intervention, the link between emerging AD-pathology and earliest clinical symptoms remains 
largely unclear. In the current study we therefore investigated the regional co-localization of iron and β-
amyloid plaques, and their relationship to cognitive performance in healthy older adults. 
116 older adults (mean age 75±7.4 years) received neuropsychological testing to calculate a global 
cognitive performance score incorporating major cognitive domains. All participants were scanned on a 
combined PET-MRI, including T1-sequences for anatomical mapping, quantitative-susceptibility-mapping 
(QSM) for assessing iron, and 18F-Flutemetamol-PET for estimating β-amyloid plaque-load. Biological 
parametric mapping (BPM) was used to generate masks indicating voxels with significant (p-FDR<0.05) 
correlation between susceptibility and 18F-Flutemetamol-SUVR. 
We found a bilateral pattern of clusters with significant regional correlations between measured magnetic 
susceptibility and 18F-Flutemetamol-SUVR, indicating co-localized iron and β-amyloid plaques. For two 
bilateral clusters, located in the frontal and temporal cortex, significant relationships (p-FDR<0.05) 
between local β-amyloid and cognitive performance could be observed. No relationship between global β-
amyloid burden and cognitive performance was observable. 
Thus we report for the first time the effect of a co-localization of iron-load and β-amyloid plaques on the 
relation between regional β-amyloid plaque-load and cognitive performance in healthy older adults. Further 
studies are needed to clarify the pathological correlates of this local interaction of β-amyloid with iron.   
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9.2 Introduction 
The accelerated accumulation of amyloid-beta (Aβ) into β-amyloid plaques is an early observable 
pathological hallmark of Alzheimer’s Disease (AD) (Roberts et al. 2017) and recent studies have 
demonstrated a close relationship between the individual level of β-amyloid plaque burden and increased 
risk for AD (Jansen et al. 2015; Pietrzak et al. 2015). According to current hypothetical models, Aβ may 
trigger several downstream pathologies implicated in neurodegeneration, including aggregation of 
pathological tau, vascular damage and neuroinflammation (Sperling et al. 2011; Serrano-Pozo et al. 2016; 
Jagust et al. 2009; Dubois et al. 2016). Recent clinical trial data suggest that the therapeutic removal of β-
amyloid may prevent cognitive decline, if performed early enough (Sevigny et al. 2016). However, novel 
diagnostic measures are needed to better understand the link between clinically silent AD pathology and 
first cognitive changes (Mortamais et al. 2017). 
There are a number of clinical studies that demonstrate that the risk for cognitive decline due to AD-
pathology is significantly increased by concurrent neurodegeneration (Jagust 2016; Mormino, Betensky, 
Hedden, Schultz, Amariglio, et al. 2014). Here, iron may provide useful information as recently published 
studies suggest a link between increased cerebral iron burden and AD related cognitive decline (Ayton et 
al. 2015; van Bergen, Li, et al. 2016; Ayton et al. 2017; Kim et al. 2017). Aβ in its monomeric and 
aggregated forms can bind iron, converting Fe3+ into Fe2+, which builds up inside and on the border of the 
plaques (Everett et al. 2014; Derry and Kent 2017; Peters, Connor, and Meadowcroft 2015) possibly 
triggering ferroptosis (Dixon et al. 2012). Additionally, this process accelerates the extent and speed of 
aggregation from Aβ monomers into β-amyloid plaques (Peters, Connor, and Meadowcroft 2015; Everett 
et al. 2014). Iron associated with β-amyloid plaques has been commonly observed and could be a possible 
source of the observed oxidative damage in AD brains (Nunomura et al. 2001; Andersen, Johnsen, and 
Moos 2014; Meadowcroft et al. 2009; Rottkamp et al. 2001; Derry and Kent 2017). Furthermore, iron has 
also been observed in activated microglia surrounding β-amyloid plaques in the absence of microbleeds 
(Zeineh et al. 2015). Activated pro-inflammatory microglia have been correlated to β-amyloid associated 
neurodegeneration and cognitive impairment (Serrano-Pozo et al. 2016; Fan et al. 2017), suggesting that in 
vivo measures of iron may be able to indicate both oxidative stress and β-amyloid associated 
neurodegeneration (van Bergen, Li, et al. 2016; Ayton et al. 2017). Small-vessel cerebrovascular disease 
(SVCD) is a frequent finding both in AD and in populations at risk for AD, therefore local hemosiderin 
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deposits resulting from vascular leakage may be another cause of local iron accumulation (Thal, Attems, 
and Ewers 2014; Young, Halliday, and Kril 2008; Guzman et al. 2013; Provenzano et al. 2013).  Recent 
developments in quantitative susceptibility mapping (QSM) techniques (Deistung, Schafer, et al. 2013; Li, 
Wu, and Liu 2011; Lim et al. 2013; Schweser et al. 2012) allow for assessment of relative iron-load in vivo. 
By using non-invasive susceptibility measures, we and others recently have demonstrated interactions 
between iron and β-amyloid pathology, that may predict longitudinal cognitive performance (Ayton et al. 
2017; Derry and Kent 2017; Van Bergen et al. 2017; van Bergen, Li, et al. 2016). However, it still remains 
unclear, whether the interaction between iron and β-amyloid takes place on a global or local level, and also 
whether this interaction may be used to infer on the present cognitive status of healthy older adults. 
Therefore, this study cross-sectionally investigated a population of cognitively healthy older adults to 1) 
investigate region-specific correlations between changes in iron, measured by QSM, and β-amyloid plaque-
load, measured by 18F-Flutemetamol-PET, on the voxel-level; 2) investigate whether susceptibility 
measures are associated with presence of SVCD, as a potential source of local iron-load changes; 3) 
determine if iron mediates the effect of β-amyloid plaque-load on cognitive performance in cognitively 
healthy older adults. 
9.3 Methods 
9.3.1 Participants 
For the current study, two cohorts at the Hospital for Psychogeriatric Medicine and Institute for 
Regenerative Medicine (IREM), University of Zurich (UZH), Switzerland were combined resulting in a 
total sample of 116 healthy and cognitively unimpaired older participants. Study procedures were in 
concordance with Human Research Act of Switzerland as well as with the declaration of Helsinki. Written 
informed consent was obtained from all participants before inclusion in the study. 
Inclusion criteria were: preserved everyday functioning and no significant cognitive impairment, as 
assessed by the CERAD neuropsychological battery (Sotaniemi et al. 2012) and additional tests used in 
earlier studies of ours (van Bergen, Li, et al. 2016; Van Bergen et al. 2017), including Mini Mental State 
Examination (MMSE), Verbal Learning and Memory Test (VLMT), Boston Naming Test (BNT), Trail 
Making Test B/A (TMT), and Stroop inference test.  
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Exclusion criteria included: significant medication or drug abuse with possible effects on cognition, 
inability to partake MRI, MRI scans with the evidence of infection or infarction, clinically relevant changes 
in red blood cell count, serious medical or neuropsychiatric illness and significant exposure to radiation. 
To have a single measure indicating cognitive performance, neuropsychology results were converted to z-
scores and averaged for the TMT, VLMT Delayed Recall, CERAD Fluency and Stroop Interference color-
word tests. These tests were selected because they encompass cognitive domains that are affected early in 
individuals suffering from cognitive decline due to AD (Albert et al. 2011), such as verbal episodic memory, 
executive function and language function. 
9.3.2 MRI data acquisition 
All participants were scanned using a 3T GE SIGNA PET-MR whole-body scanner (GE Medical Systems, 
Milwaukee, WI, USA) equipped with an 8-channel head coil. T1-weighted BRAVO images (TI=450ms, 
voxel size=1x1x1mm3, flip-angle=12°, ASSET factor=2, scan time=6:00min) were acquired for 
anatomical referencing and automated image segmentation. MR phase measurements used for QSM 
calculation were acquired using a multi-echo 3D gradient recalled echo (GRE) sequence with 6 echoes 
(TR/TE1/ΔTE=40/6/4ms, voxel size=1x1x1mm3, flip angle=15°, bandwidth=±62.5 kHz, flow 
compensated, ASSET factor=2, scan time=7:53min). Phase data acquired with an echo time in the range of 
18-26ms was used for QSM reconstruction. Images used to determine WMH were acquired using a CUBE 
FLAIR sequence (TR=6500ms, TE=134, ARC factor=2, voxel size=1x1x1.2mm3, bandwidth=±31.25 kHz, 
scan time=6:07min).  
9.3.3 Effects of structure volume 
The T1-weighted image was segmented using a multi-atlas matching approach consisting of 143 Regions 
of Interest (ROIs) developed as part of the Johns Hopkins University brain atlas. The atlas system is 
optimized for the parcellation of potential non-healthy brains by applying a Multiple-Atlas Likelihood 
Fusion algorithm and Ontology Level Control technology on the JHU multi-atlas sets (Djamanakova et al. 
2014; Tang et al. 2013; Mori et al. 2016). Specifically, the atlas set of 26 participants aged between 50 and 
90 years was used.  
To normalize different brain sizes across participants, individual structural volume was corrected with the 
following approach: Corrected structure volume = Original structure volume × (whole sample mean 
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intracranial volume / participant intracranial volume) (van Bergen, Li, et al. 2016). To investigate possible 
relationships between structure volume and local β-amyloid plaque-load or local iron-load, twelve gray-
matter regions of interest (ROIs) were selected from the generated atlas (Van Bergen et al. 2017) based on 
earlier reports on distribution of brain pathology at early stages of AD (Frisoni et al. 2010; Serrano-Pozo et 
al. 2011). ROI-masks were eroded with two pixels to account for partial volume effects before being used 
as a mask to analyze average iron-load (QSM) and β-amyloid burden. For each of the selected ROIs, 
structure volume was used as outcome variables with local β-amyloid burden and local iron-load as 
predictors, respectively. These and further correlation analyses in this work were corrected for age and 
gender after which False Discovery Rate (FDR) correction for multiple testing (Benjamini and Hochberg 
1995) was applied to the resulting p-values in each instance. 
9.3.4 Quantitative susceptibility mapping (QSM) for measuring brain iron-load 
Multiple processing steps were performed to calculate from the acquired MR phase images the quantitative 
susceptibility maps of which local cerebral iron-load was assessed. First, phase unwrapping was performed 
using Laplacian based phase unwrapping (Li, Wu, and Liu 2011). A brain mask was then obtained by skull-
stripping the GRE magnitude image acquired at TE of 14ms using FSL's brain extraction tool (BET, FMRIB 
Oxford, UK). The unwrapped phase images were then divided by 2π*TE to obtain an image of the 
frequency shift in Hz for each echo. Subsequently, background fields were eliminated with the sophisticated 
harmonic artifact reduction for phase data (SHARP) (Schweser et al. 2011) approach using a variable 
spherical kernel size with a maximum radius of 4mm and a regularization parameter of 0.05 (Schweser et 
al. 2011; Wu, Li, Guidon, et al. 2012). After removal of background fields, the resulting images of the three 
echoes were averaged to obtain a higher SNR as compared to single echo reconstruction (Wu, Li, Avram, 
et al. 2012). Inverse dipole calculations to obtain the susceptibility maps were performed using an iLSQR 
based minimization (Li et al. 2015). The means of the standard deviations of susceptibility in commonly 
accepted QSM reference regions, such as various white matter bundles and sections of the cerebrospinal 
fluid, were evaluated to select the region with the lowest mean standard deviations as the reference region 
(Deistung, Schafer, et al. 2013). For clarity and consistency with earlier studies, changes in susceptibility 
values will be referred to as changes in iron-load, due to the previously demonstrated correlation of 
susceptibility values with tissue iron-load in brain gray matter (Deistung, Schafer, et al. 2013; Li, Wu, and 
Liu 2011; Lim et al. 2013; Schweser et al. 2012). 
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9.3.5 Flutemetamol-PET for estimation of brain β-amyloid plaque burden 
Flutemetamol-PET was used to estimate individual local brain β-amyloid plaque burden (Vandenberghe et 
al. 2010). Individual dose of 140MBq of Flutemetamol was injected into the cubital vein. Time-of-flight 
algorithm including necessary corrections were applied to reconstruct the PET-images. Standard MRAC 
images were used to derive attenuation correction maps according standard manufacturer implemented 
algorithms. Late frame (minutes 85-105) values were standardized by the cerebellar gray matter value 
(Vandenberghe et al. 2010), resulting in 3D-volumes of Flutemetamol retention as an estimate of β-amyloid 
burden via standard uptake value ratios (SUVR) (matrix=256x256x89, voxel size=1.2x1.2x2.78mm3).  
9.3.6 Biological Parametric Mapping (BPM) 
To normalize the QSM and PET data of all participants to MNI space a multi-atlas matching approach 
developed as part of the Johns Hopkins University brain atlas was used. The atlas system is optimized for 
the parcellation of potential non-healthy brains by applying a Multiple-Atlas Likelihood Fusion algorithm 
and Ontology Level Control technology on the JHU multi-atlas sets (Djamanakova et al. 2014; Tang et al. 
2013; Mori et al. 2016). To limit the analysis to gray matter, a mask was generated from the tissue maps 
generated during the normalization to MNI space. The images were smoothed using a 4 mm FWHM 
Gaussian kernel limited to the gray matter mask in SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12) running under MATLAB R2016b (Mathworks, Natick, 
MA). The normalized PET and QSM images and the mask were then used as inputs for the Robust 
Biological Parametric Mapping toolbox (https://www.nitrc.org/projects/rbpm/) (Casanova et al. 2007; 
Yang et al. 2011a) running under MATLAB R2010b. The analysis was performed using the following 
settings: robust Huber regression analysis correcting for age and gender with proportional threshold set to 
0.1. The results were tested using positive sign T-test, selecting voxels where the p-FDR-corrected<0.05 
with a cluster-threshold of 100 voxels.  
9.3.7 Assessment of SVCD by semi-automated WMH detection 
To assess general occurrence of WMH, each participant’s FLAIR images were segmented into gray matter 
and major white matter regions using the previously generated atlas. The WMH in each white matter region 
were automatically identified by segmenting and grouping voxels with intensities 1.5 standard deviation 
above the average gray matter intensity of each participant (Iorio et al. 2013). Automatically segmented 
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regions were then manually validated, for example to only count a WMH in one region when it extended 
with a small number of voxels into a second white matter region. The SVCD-burden was inferred on by 
summing the number of regions exhibiting WMH.  
9.3.8 Whole cortex- and local-effects analysis 
Single measures of individual cortical β-amyloid burden and iron-load were calculated for each participant 
based on average gray-matter ROI values of 18F-Flutemetamol-SUVR and susceptibility, respectively, as 
reported earlier (van Bergen, Li, et al. 2016; Van Bergen et al. 2017). Clusters resulting from the BPM 
analysis were extracted and used as masks to extract regional iron-load changes and β-amyloid plaque-load. 
To identify "amyloid-positive" (Aβ+) or “amyloid-negative” (Aβ-) status based on single measures and 
regional gray matter 18F-Flutemetamol-SUVR values, the cutoff value of 1.562 was used (Vandenberghe 
et al. 2010). For each cluster, the combined neuropsychological score was compared between Aβ+ and Aβ- 
using a 1-way MANCOVA with age and years of education as covariates. To investigate effects of APOE4, 
the analysis was also performed on APOE4 carriers and non-carriers separately.  
To test the interaction of SVCD and iron-load, the cortical and regional iron-load was correlated with the 
WMH-score. All statistical tests were performed in MATLAB R2016b. 
9.4 Results 
9.4.1 Characteristics of the studied populations and neuropsychological performance.  
Demographic information for the investigated study population and neuropsychological test performance 
at time of inclusion are summarized in Table 1. Clinical examination revealed self-reliance and absence of 
cognitive impairment for all participants. APOE4 carrier status was only available for 105 out of 116 
participants, of those 105 there were 24 APOE4 carriers (22%).  
  
 
85 
A) Demographics  
N (M/F) 116 (69/47) 
Age (min-max) 74.81 ± 7.52 (51-95) 
Education 15.28 ± 2.76 
ApoE-e4 carriers 24 (out of 105, 22%) 
β-amyloid plaque-load (SUVR) 1.28 ± 0.32 
amyloid-positive 18 (16%) 
  
B) Neuropsychology  
MMSE 28.99 ± 1.10 
Boston Naming Test 2.56 ± 0.75 
Trail making test B/A 2.63 ± 1.26 
VLMT: Delayed recall 8.51 ± 4.04 
CERAD: Word list recall 7.32 ± 1.61 
CERAD: Word list learning 8.31 ± 1.13 
CERAD: Fluency 21.78 ± 6.34 
Stroop Interference: color-word 31.90 ± 11.53 
Table 1: Overview of sample A) demographics and B) neuropsychological test performance measures as 
mean ± STD.  
9.4.2 Effects on structure volume 
Significant negative correlation between structure volume and local β-amyloid plaque burden was found in 
the globus pallidus (p=0.001, Table 2). None of the cortical or memory regions showed significant 
correlations of volume with iron-load or β-amyloid plaque burden. 
Correlation of structure size with: β-amyloid plaque burden Iron-load 
Amygdala p=0.22  r=0.17 p=0.78  r=-0.07 
Hippocampus p=0.82  r=0.03 p=0.21  r=0.17 
Entorhinal Cortex p=0.81  r=0.05 p=0.21  r=-0.17 
Post Cingulate p=0.82  r=0.04 p=0.97  r=0.01 
Thalamus p=0.80  r=-0.06 p=0.38  r=-0.13 
Caudate p=0.82  r=-0.02 p=0.21  r=-0.19 
Putamen p=0.53  r=-0.11 p=0.21  r=-0.18 
Globus Pallidus p<0.01  r=-0.36 * p=0.96  r=-0.03 
Frontal Cortex p=0.43  r=0.13 p=0.96  r=0.02 
Temporal Cortex p=0.09  r=0.19 p=0.78  r=0.08 
Parietal Cortex p=0.80  r=-0.06 p=0.21  r=-0.17 
Occipital Cortex p=0.82  r=0.02 p=0.96  r=0.03 
Table 2: Regional correlation analysis for structure volume with the local β-amyloid plaque burden and 
iron-load. Indicated are values for the entire sample (n=116), * indicates a significant correlation with p-
FDR-corrected < 0.05; 
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9.4.3 Biological Parametric Mapping (BPM) 
Deep frontal white matter was found to have the lowest average susceptibility standard deviations and was 
selected as a reference region to assess relative iron-load for each participant, with iron-load defined as the 
magnetic susceptibility in ppm relative to this region. The BPM analysis of correlation between iron-load 
(susceptibility) and β-amyloid plaque-load (18F-Flutemetamol-SUVR) resulted in 37 clusters of at least 
100 voxels with p-FDR-corrected < 0.05. Graphical representation of the clusters is shown in Figure 1 
projected onto a 3D brain and on two exemplary axial slices. Additional axial slices throughout the whole 
brain can be seen in Figure 2. Alternatively, the number of significant voxels in brain regions are listed in 
Table 3, using the coarse region separation of the Hammers maximum probability atlas (Hammers et al. 
2003). The strongest correlations were found in the basal ganglia structures. Many clusters were bilateral 
in nature and no differences were observed in number or size of clusters between hemispheres.  
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Figure 1: Overlay of regions with significant correlation between iron-load (susceptibility) and β-
amyloid plaque-load (18F-Flutemetamol-SUVR) with p-FDR-corrected<0.05 and a cluster-threshold of 
100 voxels, on a 3D brain (A) and on two exemplary slices (B). Extracted β-amyloid plaque-load of 
regions (1) and (2) indicated in (B) identifies Aβ+ with significantly lower cognitive performance 
compared to Aβ- participants.  
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Figure 2: Overlay of regions with significant correlation between iron-load (susceptibility) and β-
amyloid plaque-load (18F-Flutemetamol-SUVR) with p-FDR-corrected<0.05 and a cluster-threshold of 
100 voxels. 
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Region # Region Name 
Voxels 
Significant 
Percentage of 
Region 
59 Superior frontal gyrus - Right 3690 8% 
58 Superior frontal gyrus - Left 3378 7% 
50 Precentral gyrus - Left 3258 11% 
38 Putamen - Left 3076 74% 
35 Caudate nucleus - Right 2879 77% 
39 Putamen - Right 2786 69% 
51 Precentral gyrus - Right 2661 9% 
34 Caudate nucleus - Left 2519 69% 
56 Inferior frontal gyrus - Left 2187 13% 
62 Superior parietal gyrus - Left 2073 6% 
12 Superior temporal gyrus, posterior part - Left 2065 17% 
23 Lateral remainder of occipital lobe - Right 1545 4% 
11 Superior temporal gyrus, posterior part - Right 1461 11% 
31 Posterior temporal lobe - Right 1453 3% 
57 Inferior frontal gyrus - Right 1328 8% 
22 Lateral remainder of occipital lobe - Left 1297 3% 
17 Cerebellum - Right 1295 2% 
63 Superior parietal gyrus - Right 1205 3% 
61 Postcentral gyrus - Right 1160 5% 
33 Inferiolateral remainder of parietal lobe - Right 1076 3% 
40 Thalamus - Left 1068 17% 
60 Postcentral gyrus - Left 1053 4% 
66 Cuneus - Left 893 11% 
30 Posterior temporal lobe - Left 871 2% 
41 Thalamus - Right 839 14% 
29 Middle frontal gyrus - Right 836 2% 
28 Middle frontal gyrus - Left 663 1% 
67 Cuneus - Right 606 7% 
18 Cerebellum - Left 568 1% 
25 Cingulate gyrus (gyrus cinguli), anterior part - Right 530 7% 
70 Lateral orbital gyrus - Left 512 16% 
32 Inferiolateral remainder of parietal lobe - Left 473 1% 
71 Lateral orbital gyrus - Right 420 11% 
54 Anterior orbital gyrus - Left 417 7% 
10 Parahippocampal and ambient gyri - Left 359 9% 
43 Pallidum - Right 237 21% 
72 Posterior orbital gyrus - Left 237 6% 
14 Middle and inferior temporal gyrus - Left 235 1% 
73 Posterior orbital gyrus - Right 228 5% 
44 Corpus callosum 223 1% 
42 Pallidum - Left 195 18% 
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19 Brainstem 156 1% 
26 Cingulate gyurs (gyrus cinguli), posterior part - Left 152 2% 
2 Hippocampus - Left 148 8% 
13 Middle and inferior temporal gyrus - Right 135 1% 
4 Amygdala - Left 131 10% 
8 Anterior temporal lobe, lateral part - Left 123 4% 
24 Cingulate gyrus (gyrus cinguli), anterior part - Left 110 2% 
77 Subgenual frontal cortex - Right 110 10% 
68 Medial orbital gyrus - Left 100 2% 
 
Table 3: Brain regions (Hammers maximum probability atlas, (Hammers et al. 2003)) included by voxel-
clusters characterized by significant correlation between iron content (QSM) and A-beta plaque density 
(18F-Flutemetamol SUVR). Brain regions are ordered by the number of significant voxels. 
9.4.4 Whole cortex- and local cluster-effects analysis 
The cutoff for 18F-Flutemetamol-SUVR (Vandenberghe et al. 2010) identified 18 participants (16%) 
"amyloid-positive" (Aβ+) and 98 “amyloid-negative” (Aβ-) based on whole cortex β-amyloid plaque-load. 
The Aβ+ participants that were identified using whole cortex β-amyloid plaque-load did not perform 
significantly worse than the Aβ- participants on the cognitive performance score (Figure 3A). 
Out of the 37 clusters identified using the BPM analysis, two bilateral clusters in the frontotemporal cortex 
showed significantly lower cognitive performance scores in the Aβ+ group that was identified using local 
cluster β-amyloid plaque-load (p-FDR-corrected < 0.05, clusters indicated in Figure 1B). In the frontal 
cortex cluster 8 participants with significant lower (p=0.012, Figure 3B) cognitive performance score were 
identified. Similarly, in the temporal cortex cluster 18 participants with significant lower (p=0.049, Figure 
3C) cognitive performance were identified. APOE4 status did not split either the whole-cortex or regional 
β-amyloid plaque-load based Aβ+ or Aβ- groups into sub-groups with significant differences between sub-
groups. 
From the bilateral clusters in the frontal and temporal cortex regional iron-load and β-amyloid plaque-load 
measures are shown in figure 4A and B. The WMH-score did not correlate with whole cortex iron-load or 
the extracted iron-load from the two clusters (p > 0.05, figure 4C and D). Splitting these correlation 
analyses by APOE4 status did not result in significant different correlations when using Fisher’s r-to-z 
transformation on the correlation coefficients (Fisher 1921). 
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Figure 3: Cognitive performance score for participants grouped as Aβ+ or Aβ- based on the -amyloid 
plaque-load (18F-Flutemetamol-SUVR) in the (A) whole cortex, (B) frontal cortex cluster and (C) 
temporal cortex. * = p < 0.05, n.s. = non-significant difference. 
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Figure 4: Extracted iron-load (susceptibility) and β-amyloid plaque-load (18F-Flutemetamol-SUVR) for 
(A) frontal cortex cluster and (B) temporal cortex clusters found using BPM analysis. Non-significant 
correlation between vascular burden and iron-load in (C) frontal cortex cluster and (D) temporal cortex 
clusters. 
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9.5 Discussion 
In this study we investigated the co-localization and correlation of regional iron- and β-amyloid plaque-
load by assessing neuroimaging markers in a voxel-based BPM analysis. We showed that strong 
correlations between iron-load and β-amyloid plaques are present in a bilateral pattern that particularly 
includes clusters located in the frontotemporal cortex and basal ganglia. Moreover, β-amyloid plaque-load 
in frontotemporal clusters was inversely associated with global cognitive performance scores. Interestingly, 
within these clusters, there was no association between SVCD and local susceptibility measures. To our 
knowledge this is the first study that shows the effect of a co-localization of iron-load and β-amyloid plaques 
on the relation between regional β-amyloid plaque-load and cognitive performance in healthy older adults. 
This co-localization of iron-load and β-amyloid plaques is consistent with earlier considerations on iron as 
a reflection of synergistic pathologies that promote β-amyloid-toxicity in vulnerable brain regions (Derry 
and Kent 2017; Ayton et al. 2017; Peters, Connor, and Meadowcroft 2015). As these findings were present 
in a cross-sectional sample, local susceptibility as a marker of the β-amyloid effects on cognitive 
performance might be used to separate disease stages.  
Earlier studies by Ayton et al. that included longitudinal cognitive performance assessments (Ayton et al. 
2017; Ayton et al. 2015; Derry and Kent 2017) indicate relevance of the association between iron and β-
amyloid for cognitive decline and risk for AD. Brain regions affected by the here reported co-localization 
are consistent with regional effects reported earlier both for iron (Cho et al. 2016; Ayton et al. 2017) and 
general vulnerability for AD-pathology (Serrano-Pozo et al. 2011).  
The relationships of structure volume in globus pallidus with β-amyloid plaque-load overlaps with the 
strongest region of correlation between β-amyloid plaque-load and iron-load found using the BPM analysis. 
When the data was not corrected for age, there was a significant negative correlation between iron-load and 
structure volume in the basal ganglia (p-FDR-corrected<0.05, data not shown) which seems to indicate both 
pathologies are, possibly synergistically, affecting this structures throughout the investigated age range. 
These findings are consistent with earlier observations of increased iron deposition in basal ganglia 
structures during aging (Hallgren and Sourander 1958; Bartzokis et al. 1997). 
While only two bilateral regions showed the ability to differentiate low cognitive performers, these regions 
were located in cortical structures commonly affected by AD (Albert et al. 2011; Braak and Braak 1991). 
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No significant effect on cognition was observable for global β-amyloid burden in our study, similar to 
earlier reports of weak associations between β-amyloid plaque-load and cognition in cognitively healthy 
cross-sectional samples (Mortamais et al. 2017). However, our finding of significant effects of local β-
amyloid in frontotemporal regions of cognitively healthy participants may be consistent with the spatio-
temporal spread of disease pathology in neurodegenerative diseases (Brettschneider et al. 2015). As we 
only could observe the effect of β-amyloid on cognition when using iron to define the spatial clusters, iron 
might function as a mediating factor of β-amyloid plaque effects on cognition. Taking into account that β-
amyloid plaque burden can be present in cognitively healthy older dults and reflects risk for progression to 
AD (Jansen et al. 2015), iron-load may be a potential marker for linking β-amyloid plaque burden to 
variation in cognitive performance, and thus may potentially be used to identify subtle dysfunction as very 
first manifestation of pre-clinical AD (Mortamais et al. 2017). While predictive value of QSM for cognitive 
decline has been demonstrated recently (Ayton et al. 2017; Kim et al. 2017), our current findings suggest 
informative value of local iron as a state marker of individual risk for cognitive decline due to cerebral 
amyloidosis. 
Recent efforts in validation of the QSM technology make it possible to quantitatively assess regional iron-
load in vivo (Deistung, Schafer, et al. 2013; Langkammer et al. 2012) and assess iron in a context of 
neurodegenerative disease (van Bergen, Li, et al. 2016; van Bergen, Hua, et al. 2016; Acosta-Cabronero et 
al. 2013; Ayton et al. 2017). When interpreting the susceptibility data, it needs to be considered that the 
iron-load could vary on an inter-voxel basis and that QSM is biased by decreased myelin density 
(Langkammer et al. 2012; Liu, Li, et al. 2011). Myelin loss could be substantial in the deep frontal white 
matter QSM reference region, however, myelin loss would increase average susceptibility in the reference 
region and thus lead to underestimation of the gray matter iron measures. The gray matter regions 
investigated in this study are low in myelin content and thus the myelin contribution in these regions was 
considered negligible and even potentially underestimated. Efforts were made to limit spillover of white 
matter signal of both QSM and 18F-Flutemetamol-SUVR images by performing the BPM analysis only in 
the gray matter, and selecting only clusters larger than 100 voxels. Optimized normalization to MNI space 
was performed to assure adequate input to the BPM analysis, but potential effects of the normalization 
process on the result cannot be fully excluded. However, distortion by processes of co-registration of PET 
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with MRI images or bias due to changes occurring in the time between PET and MR acquisition could be 
avoided as the respective measures were acquired using an integrated PET-MRI.  
Interestingly, we find no correlations between iron and SVCD throughout the brain, potentially confirming 
that the measured iron-load is not a measure of extravasated hemoglobin and vascular pathology. 
Considering earlier reports on iron containing activated microglia, and microglia as a promotor of β-
amyloid plaque toxicity (Serrano-Pozo et al. 2016; Zeineh et al. 2015), local neuroinflammation might be 
an alternative explanation of our finding of elevated iron in the vicinity of β-amyloid plaques. However, 
the WMH-score used to infer upon SVCD in the gray matter is only based on occurrence of WMH and not 
size or specific location. This limitation could affect the validity of the measure and as such the results at 
this point are only indicative of potential effects of SVCD on QSM iron measures. 
Previous work by us and others did show Aβ burden-related effects of APOE4 carriers status on iron 
measures in older populations with advancing cognitive impairment (van Bergen, Li, et al. 2016; Ayton et 
al. 2017). The fact that in the current study no significant effects of APOE4 were observable is most likely 
caused by a low number (all N<5) of APOE4 carriers in the Aβ+ groups, thus reducing statistical power. 
Additionally, the investigated sample showed no signs of cognitive impairment and spanned a large age-
range which also could limit the effects of APOE4 status, as reported earlier (Corrada et al. 2013; Garibotto 
et al. 2012). 
To conclude, in this cross-sectional study we have demonstrated that the co-localization of markers for iron 
and β-amyloid plaques characterizes brain regions where β-amyloid plaque-load inversely relates to the 
individual cognitive performance level. While the individual risk for AD-dementia has been demonstrated 
to relate to total β-amyloid burden (Roberts et al. 2017; Pietrzak et al. 2015), we here demonstrate a regional 
impact of β-amyloid on brain functionality characterized by iron-load in a non-demented older adult 
population. Further histological and molecular imaging studies are needed to characterize the interplay 
between iron and various other downstream pathologies that are possibly implicated in conferring local β-
amyloid related neuronal damage.   
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10 Discussion 
In this cumulative work we tried to investigate the role of iron in pre-clinical AD using neuroimaging 
markers. Neuroimaging iron measures and the associated post-processing were successfully implemented 
both at 7T and at the 3T PET-MRI. In the next sections, we will summarize for each of the previously 
postulated hypotheses what results were obtained. 
10.1 Iron accumulation in human brains co-localizes with β-amyloid plaques in 
healthy and pre-clinical Alzheimer’s disease subjects independent from 
iron accumulations due to microbleeds. 
An important question in the field of iron-neuroimaging is the source of the measured iron-load signal. Iron 
sources can be either tissue-specific or hemosiderin leftovers of previously occurring microbleeds. In 
particular in the aging brain WMH are often found due pathological degradation of the vasculature. The 
WMH-score implemented for the current studies is intended as an indication of vascular integrity and as 
such the possible presence of deposits of extravasated hemoglobin. The current implementation is relatively 
crude and while it was not correlated to any of the iron-load measures, it cannot be concluded that the iron-
load measures are not due to some form of microbleeds. The diagnostic value of WMH in pre-clinical and 
early stage AD has been investigated in several samples and results indicate a strong link between the two 
(Agosta et al. 2011; Esiri et al. 2015; Guzman et al. 2013; Holland et al. 2008; Provenzano et al. 2013; 
Yoshita et al. 2006; Young, Halliday, and Kril 2008). In general, the link between vascular dysfunction and 
AD is not only strong due to CAA but also because the most common risk factors for AD are related to the 
vasculature: APOE4 status, hypertension, hypotension, diabetes and hypercholesterolemia (Dickstein et al. 
2010).  
The WMH-score has given us an indication that the regional iron-load is not entirely dependent on vascular 
damage. Specifically, in the oldest-old population we found decreased cortical iron-load, despite their more 
than two-fold higher occurrence of WMH. Further research using histology is required to investigate the 
relationship between (white matter) vascular damage and QSM iron-load measures. However, previous 
studies have shown that abnormal iron accumulation and presence of iron within activated microglia also 
occurs in the absence of microbleeds (Zeineh et al. 2015; Meadowcroft et al. 2009). With these pathology 
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findings and our oldest-old findings, there are enough grounds to interpret iron findings separate from 
vascular pathology.  
We were the first to show correlations of neuroimaging markers in an MCI sample, using the enhanced data 
quality of 7T MRI (van Bergen, Li, et al. 2016). We repeated this at 3T using the PET-MRI, allowing for 
voxel-wise correlation (BPM) analysis that revealed strong bi-lateral clusters of co-localized iron and β-
amyloid plaques. This is the first study of this scale that was able to detect these voxel-wise correlations 
due to the benefits of the PET-MRI, allowing for truly simultaneous assessment of iron and β-amyloid 
plaques. 
Limiting factor in the analysis is that the neuroimaging markers used cannot differentiate between 
intercellular, extracellular or bound iron. Thus, within the measured imaging voxels that were 1x1x1mm3, 
the iron could be either inside microglia (Zeineh et al. 2015), stored in ferritin or bound to β-amyloid plaques 
(Rottkamp et al. 2001). 
10.2 Iron accumulation co-localized with β-amyloid plaques in human brains 
negatively affects cognitive performance in healthy and pre-clinical 
Alzheimer’s disease subjects. 
While the individual risk for AD-dementia has been demonstrated to relate to total β-amyloid burden in 
some studies (Roberts et al. 2017; Pietrzak et al. 2015), the neurodegenerative and cognitive effects of this 
pathology do not correlate to cognitive performance in all individuals (Jansen et al. 2015). Build-up of β-
amyloid plaque does not occur in all brain regions simultaneously, some regions are affected earlier than 
others and spread of pathology is faster between functionally connected regions (Thal, Attems, and Ewers 
2014; Seeley et al. 2007; Seeley et al. 2009). This supports considerations that region specific measures of 
β-amyloid plaque-load could be more predictive of cognitive decline (Brettschneider et al. 2015). 
Chronologically, we found the first evidence of the effect of co-localized iron and β-amyloid on cognitive 
performance in the 7T MRI results. Here subjects with a clinical diagnose of MCI showed local correlation 
between iron and β-amyloid plaque-load in a functionally affected region (see 10.3). However, the clinical 
diagnose of MCI is not limited to AD-MCI (Albert et al. 2011) and thus makes it hard to draw conclusions 
regarding the actual effects of iron in pre-clinical AD. 
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The first 3T project involving oldest-old participants without signs of cognitive decline revealed that lower 
cortical iron-load might play a role in their successful aging (Van Bergen et al. 2017). Of particular interest 
was the very high β-amyloid plaque-load in the oldest-old, which was for some subjects in the same range 
as normally seen in AD (Vandenberghe et al. 2010). While one cannot directly conclude that lower cortical 
iron has protected the oldest-old from AD-pathology, it can still be seen as a marker of lower inflammation 
and other active neurodegenerative processes (Andersen, Johnsen, and Moos 2014). Additionally, the lack 
of correlation between SVCD-burden and iron-load is a conformation that what we observed is potentially 
a real protective effect and not a simple consequence of SVCD. Apart from SVCD, many physiological 
factors (life-style, diet, blood pressure, medication, etc.) and non-physiological factors (formal education, 
cognitively challenging environments, etc.) might have influenced the brain’s state at this highest age 
(Nyberg et al. 2012) and as such conclusions are still speculative. It is an intriguing result that warrants 
further exploration to clarify the factors that affect the build-up, clearance and downstream effects of 
cortical iron. 
The larger sample BPM analysis added to the oldest-old results by showing that local β-amyloid plaque-
load in clusters of strong correlation between iron and β-amyloid plaque, show significant differences in 
cognitive performance between Aβ+ and Aβ- subjects. In this same sample, using the cortical β-amyloid 
plaque-load did not result in significantly different performance between the two groups. 
10.3 Iron accumulation in human brains correlates with changes in functional 
connectivity between brain regions measured by fMRI. 
Changes in brain connectivity measured with fMRI have been identified in several studies, revealing large 
differences between AD and healthy controls but is also able to identify preclinical disease stages (Agosta 
et al. 2012; Binnewijzend et al. 2012; Damoiseaux et al. 2012; Franzmeier et al. 2016; Koch et al. 2012; 
Sheline and Raichle 2013; Sheline et al. 2010; Sperling et al. 2009; Steininger et al. 2014). The region of 
altered functional connectivity found in the 7T study reveals potential effects of iron on brain functioning. 
However, in that context it is hard to draw conclusions due to the ambiguity about what increased iron 
measures potentially reflect, specifically related to brain functioning. The location in the frontal cortex and 
the strong correlations between iron and β-amyloid plaques found in this region aligns with previous 
functional connectivity work that also implicate this region in early changes. The role of iron in changes to 
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functional connectivity deserves further investigation, in order to separate other effects that could contribute 
to the observed changes. 
An attempt was made to separate contributions of several pathologies (iron, β-amyloid and SVCD) on the 
functional connectivity changes in the oldest-old study. The results show that for different regions the 
impact of each pathology differs and that combinations of the three cover the majority of the difference. 
However, the differences between the two investigated networks in how much each pathology contributed 
was large. The interplay of the three investigated pathologies is likely large and thus such overlaps are to 
be expected. It would be challenging to find enough participants having only one of the pathologies to really 
separate each pathology for further studies. Previous studies investigating functional network changes of 
β-amyloid plaque-load did not look at other pathologies and are therefore also inherently limited (Rombouts 
et al. 2005; Sheline et al. 2010; Sperling et al. 2010; Steininger et al. 2014). 
10.4 APOE-e4 genotype is associated with high β-amyloid plaque related iron 
accumulation. 
The 7T study revealed significantly higher β-amyloid plaque-load and iron-load in the MCI subjects that 
were APOE4 positive. However, the sample was relatively small and similar differences were not observed 
in the larger 3T study. It could indicate that APOE4 status only in later stages of cognitive decline affects 
iron-loading, but APOE4 status does affect β-amyloid throughout life (Morris et al. 2010). Similar to our 
3T study, the longitudinal study by Ayton et al. that investigate the effects of iron-load in more advanced 
cognitive decline did not show strong APOE4 effects on iron (Ayton et al. 2017). In several brain regions 
the study actually found the opposite effect: APOE4 positive status was associated with decreased iron-
load, although this effect was not present in all brain regions and stages of cognitive decline (Ayton et al. 
2017). Therefore, no claims of direct association of APOE4 with β-amyloid plaque related iron 
accumulation can be made at this point. 
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11 Conclusions and future directions 
With the background summarized in the introduction (4.2) and knowledge obtained in this work there is 
ample evidence of a role of iron in AD pathology, both in disease progression and as a biomarker. Iron-
load and β-amyloid plaque-load correlate throughout various brain regions, which could indicate both iron-
bound iron and activated microglia, each in their own way influencing neuropathology. However, as this 
was neuroimaging based work we cannot excluded that the observed changes result from iron being only a 
downstream marker of β-amyloid plaque pathology. Alterations in iron seem to affect disease progression, 
with decreased iron-loading being linked to preserved cognition at higher age and increased iron with faster 
progression of cognitive decline (Ayton et al. 2017; Derry and Kent 2017). 
With this in mind, the following questions arise for future investigations: 
• What is the relationship between iron and neuroinflammation? TSPO-PET tracers are able to 
give readings on activated microglia in vivo (Fan et al. 2017). Combined TSPO-PET-MRI would 
be the ideal tool to investigate if the observed iron-load is actually a marker of activated microglia 
or plaque-bound iron. As activated microglia are also present around β-amyloid plaques, this should 
be combined with histological work in humans and animals. Additionally, investigating iron-load 
in vivo and on pathology after β-amyloid removal therapy (Sevigny et al. 2016) might also provide 
insights into location and effect of the measured iron.  
• Does local iron promote spread of neurodegenerative change in AD? This question was 
partially answered by the work of Ayton et al. (Ayton et al. 2017; Derry and Kent 2017), but could 
benefit from longitudinal repeated amyloid-PET-MRI analysis. This would allow for a reading on 
β-amyloid plaque changes combined with associated iron-load changes and how they potentially 
shift during development of β-amyloid plaque pathology. 
• Does local iron promote spread of neurodegenerative change in AD? The longitudinal repeated 
amyloid-PET-MRI analysis would also allow for in vivo inferences on the “chicken-and the egg” 
problem: does iron-loading promote AD-pathology, or does AD-pathology promote iron-loading? 
• Does the co-localization of iron with β-amyloid characterize a clinical subpopulation with 
distinct therapeutic needs? It is very likely that regulation of iron and as such also dysregulation 
is subject-dependent. As described in the introduction (4.2), numerous proteins are involved in 
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handling of iron in the brain and thus can vary on an individual level. The lower levels of CSF 
ferritin in APOE4 carriers is a prime example of such differences (Ayton et al. 2015). Microglial 
activity, mobility or efficiency involved in iron clearance could be altered and accelerate disease 
progression. The previously described future directions followed up with chelation therapy in early 
disease stages could reveal if there are groups of subjects that benefit in particular from iron 
removal.  
• Is iron a good MRI based (theranostic) marker for AD? With knowledge on the previous 
problem iron measures could be used as a theranostic marker during treatment. If iron-loading 
promotes AD-pathology, early intervention by iron chelators could be tracked via MRI based iron 
measures. 
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13 Verification of original content 
The three main chapters (7, 8, 9) and the list of references were removed before uploading this work to the 
UZH Docoloc system for verification of original content. The resulting report is shown below. 
 
  
 
118 
CV 
Name: Jiri van Bergen 
Born: 28-aug-1989, Tilburg, The Netherlands 
Nationality: Dutch 
Email: jirivanbergen@gmail.com 
Address: Dörflistrasse 115, 8050, Zürich, Switzerland 
 Krijtestraat 34, 5066BH, Moergestel, Netherlands 
+41 78 816 8968  
Education 
2014-2017 PhD (Dr. sc. nat.) in Neuroscience  
 University of Zürich 
Institute for Regerenative Medicine (IREM), Neuroscience Center Zürich (ZNZ)  
  
2010-2013 Master of Science in Medical Engineering 
 Eindhoven University of Technology - University Medical Center Utrecht  
Coursework and projects focused on diagnostic sensors, MRI, nuclear imaging and image 
processing.  
2007-2010 Bachelor of Science in Biomedical Engineering  
 Eindhoven University of Technology. 
2001-2007 Secondary Education – VWO (Atheneum) 
 Odulphuslyceum, Tilburg, The Netherlands 
Work experience 
2014-2017 PhD Candidate in Neuroscience, University of Zürich and ETH Zürich 
 Title: MRI-PET for investigating cerebral iron-load and associated pathology in preclinical 
Alzheimer’s Disease (expected graduation December 2017) 
 PhD-committee: Prof. Dr. Roger M. Nitsch, Prof. Dr. Klaas P. Prüssmann, PD Dr. Paul 
Gerson Unschuld 
 Investigated the role of cortical iron-load in the pre-clinical stages of Alzheimer’s disease 
using advanced imaging techniques on both the Philips 7T MRI and the integrated GE 3T 
PET-MRI. Until very recent, cortical iron-load was considered not to be of any relevance in 
Alzheimer's Disease. The results of this work have contributed significantly to iron now being 
recognized now as an important potential marker of early disease progression before onset of 
clinical symptoms. The work was the first to demonstrate in vivo using MRI the co-localization 
of the pathological hallmark of Alzheimer's Disease (β-Amyloid) and iron [1-4, 6, 8].  
 Further collaborated with medical doctors and clinical support staff to select which state-of-
the-art MRI technologies to use in upcoming larger clinical studies. Implemented data-
processing and streamlining of the large research data volumes that were new to the research 
clinic.  
 Extensive experience with sequence development (GE-EPIC), QSM, multiband-fMRI, MRSI, 
7T-field-monitoring technology (Scope), Amyloid-PET, Tau-PET, FLAIR and ASL. 
  
 
119 
2014 (Jan-June) Research Assistant at Johns Hopkins Medical Institutions, Baltimore 
 Supervisors: Prof. Dr. Peter C. M. van Zijl and Dr. Xu Li 
 Extended the work on Quantitative Susceptibility Mapping (QSM) and adapted the 
experimental research focused processing pipeline into an easy to use toolbox. Introduced the 
toolbox to clinicians from other departments and collaborators to easily process large datasets 
without manual intervention.  
 Applied the QSM method to investigate cerebral iron-load in cohorts of Alzheimer's disease, 
ADHD and in particular Huntington’s disease subjects [5, 7]. 
Research experience 
2013 (Jan-Dec) Master thesis, Utrecht University Hospital (UMC), Utrecht  
 Supervisors: Dr.ir. Sjoerd Crijns and Prof. Dr. Klaas Nicolay 
 Combined new motion correction algorithms for MRI data to make real time tracking of tissues 
in the abdomen possible. This work facilitated real time motion correction of the radiotherapy 
treatment on the MRI-linear accelerator in the UMC. Implemented initial compressed sensing 
approach to improve quality at 2-4x additional accelerated acquisition.  
2012 (June-Nov) Internship at Johns Hopkins Medical Institutions (JHMI), Baltimore 
 Identified that single-head orientation QSM in MRI which could be used to track the disease 
progress of Multiple Sclerosis and Huntington’s disease [5, 7]. 
2012 (Jan-March) Internship Neurology at University Hospital Maastricht, Maastricht   
 Developed protocols for CHEPS EEG measurements used in the analysis of nerve 
degeneration. Identified in a small sample that mental distraction from the applied nerve 
stimuli resulted in significantly lower EEG responses and lower perceived sensation of 
identical stimuli. 
2011 (Sep-Dec) Internship at MAASTRO Advanced Radiotherapy clinic, Maastricht   
 Analyzed 4D-CT images to characterize displacement of lung tissue as a result of cardiac 
motion. The results of this study suggested that the identified motion would not affect the 
radiotherapy treatment on targets in the lungs. 
Extracurricular activities 
2010-2011 Board member of study association Biomedical Engineering, Protagoras 
 Roles: Internal affairs (committees) and Treasurer 
 Presided over the 13 committees that organized extracurricular activities. Designed and 
implemented an online registration and payment system for members to sign up for the 
activities. Managed the finances of the 500+ member study association. 
2009-2010 Study tour committee, Australia 2010 
 Organized and guided the 4-week study tour to Australia for 30 biomedical engineering 
students and 3 faculty members for the purpose of learning about the biomedical industry and 
universities in Australia. 
2008-2014 Committee work, study association Protagoras 
 Financial control committee, IT committee, Introduction committee. 
Additional experience 
2015-present Open Source Software Developer, SABnzbd 
 Developer of large multi-platform open source application with 150.000+ active users and 
around 550 new users a day. Boosted processing throughput of the software by over 150%. 
 
120 
Collaborated with a small team to handle user support, bug fixing and feature 
development. Gained strong affinity with front-end software development (HTML, CSS, 
Bootstrap, jQuery, KnockoutJS), back-end software development (Python, C), implementation 
of unit and functional testing, overseeing contributions of other developers, community 
management and release management. 
2008-2017 Teaching Assistant, Eindhoven University of Technology and University of Zürich 
 Courses: Python for Biologists, Big Images, Bio-informatics, Numerical analysis course, 
Biomechanics, MATLAB and Statgraphics. 
2005-2017 Sail Studio Web design,  
 Developer of websites and web-apps for small to medium sized businesses and nonprofit 
organizations. Communicated with the customer to meet demands, specify design-plans and 
estimations of costs. Translating ideas of customers into feasible concepts in accordance with 
budget estimations. Collaborated with front-end designers and code-specialists when projects 
were too large to handle individually. 
 Programming skills: PHP (MVC-designs), Javascript (jQuery), HTML5, CSS (Bootstrap) 
Skills 
Programming: MATLAB, Mathematica, PHP, MySQL, Javascript (jQuery, Bootstrap), HTML5, XML, 
Python, Pascal, Delphi, C++, GE-EPIC (MRI-sequences), Linux (shell, OS). 
Languages: Dutch  native speaker 
English  fluent 
German  limited working proficiency 
Publications and conference presentations 
[1] van Bergen, J., et al., 2017. Simultaneous Quantitative Susceptibility Mapping and Flutemetamol-PET reveals 
co-localization of iron and β-amyloid as a determinant of cognitive performance at high age. NeuroImage 
(submitted, under review). 
[2] van Bergen, J., et al., 2017. Low cortical iron and high entorhinal cortex volume promote cognitive functioning 
in the oldest-old. Neurobiol Aging (accepted, awaiting publication). 
[3] van Bergen, J., et al., 2017. Correlations of beta-Amyloid and brain iron-load (QSM): preliminary results of 
simultaneous assessment in a large sample. Presentation ISMRM 2017, Honolulu, Awarded ISMRM Magna 
Cum Laude Merit Award. 
[4] van Bergen, J., et al., 2016. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Sci 
Rep 6, 35514. 
[5] van Bergen, J., et al., 2016. Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest 
Huntington Disease. AJNR Am J Neuroradiol 37, 789-796. 
[6] van Bergen J., et al., 2016, Simultaneous quantitative susceptibility mapping-MRI and 18F-Flutametamol-PET 
indicate functional impact of cerebral iron and Amyloid-β plaque burden in cognitively normal super-agers. 
Presented at 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. 
[7] van Bergen, J., et al., 2015. Magnetic susceptibilities measured by Quantitative Susceptibility Mapping (QSM) 
indicate brain iron levels correlate with genetic burden in prodromal Huntington's disease . Presentation 
ISMRM 2015, Toronto, Awarded ISMRM Magna Cum Laude Merit Award 
[8] van Bergen, J., et al., 2015. Regional cerebral iron concentrations as indicated by magnetic susceptibilities 
measured with Quantitative Susceptibility Mapping (QSM) at 7 Tesla correlate with brain Aβ plaque density as 
measured by 11-C-Pittsburgh Compound B Positron-Emission-Tomography (PiB-PET) in elderly subjects at 
risk for Alzheimer’s disease (AD). Presentation ISMRM 2015, Toronto 
